Hepatitis b immunisation regimen and compositions
A combination of ChAd and MVA vectors with recombinant hepatitis B antigens and adjuvants addresses the challenge of HBsAg persistence in chronic hepatitis B by inducing effective immune responses, enabling HBsAg and HBV DNA suppression.
Patent Information
- Application Number
- JP2024135563
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-12-15
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for chronic hepatitis B infection, such as nucleoside/nucleotide analogs, fail to achieve HBsAg loss, leading to long-term therapy and increased risk of relapse, with existing vaccines and immunotherapies not effectively inducing HBV-specific CD8+ T cell responses.
A method involving sequential or simultaneous administration of replication-defective chimpanzee adenovirus (ChAd) and modified vaccinia virus Ankara (MVA) vectors encoding hepatitis B surface and core antigens, combined with recombinant antigens and adjuvants, to induce potent HBs- and HBc-specific T cell responses.
The approach effectively reduces serum HBsAg and HBV DNA levels to undetectable levels, allowing potential discontinuation of nucleos(t)ide analogs without relapse, by restoring HBV-specific immune responses.
Smart Images

Figure 2024161488000031 
Figure 2024161488000032 
Figure 2024161488000033
Abstract
Description
[Technical field]
[0001] The present invention relates to immunization regimes particularly suited for the treatment of chronic hepatitis B, methods of treating chronic hepatitis B, and compositions for use in such regimes and methods, which include the administration of compositions comprising vectors that deliver hepatitis B antigens, and compositions comprising recombinant hepatitis B antigen proteins. [Background technology]
[0002] Hepatitis B virus (HBV) infection is a major public health problem. Approximately 257 million people worldwide are infected with HBV [WHO, 2017]. The clinical course and outcome of HBV infection is driven primarily by the age at infection and the complex interplay between the virus and the host immune response [Ott, 2012; Maini, 2016]. Thus, exposure to HBV can result in acute hepatitis that resolves spontaneously or can progress to various forms of chronic infection, such as inactive hepatitis B surface antigen (HBsAg) carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) [Liaw, 2009]. The prevalence of HBsAg in the adult population is >2%, with rates of 5-8% in Southeast Asia and China, and >8% in the African region. Between 15 and 40% of individuals with chronic hepatitis B infection (defined as serum HBsAg detectable for >6 months) will develop hepatic sequelae, of which liver cirrhosis (LC), hepatic decompensation, and HCC are the main complications.
[0003] Although the implementation of prophylactic hepatitis B immunization, commonly practiced in young children, has been highly effective in reducing the incidence and prevalence of hepatitis B in many endemic countries, it has not yet led to a robust reduction in the prevalence of chronic hepatitis B infection (CHB) in adolescents and adults, and is not expected to impact HBV-related deaths until several decades after its introduction. In 2015, hepatitis B was responsible for 887,000 deaths, the majority due to cirrhosis and HCC [WHO, 2017].
[0004] Clinical management of chronic hepatitis B aims to improve survival and quality of life by preventing disease progression and, consequently, the development of HCC [Liaw, 2013]. Current therapeutic strategies are mainly based on long-term suppression of HBV DNA replication to achieve stabilization of HBV-induced liver disease and prevent progression. Serum HBV DNA levels are the underlying endpoint for all current therapeutic modalities. Although the achievement of loss of (detectable) hepatitis B e antigen (HBeAg) is another valuable biomarker, loss of HBsAg is generally considered the optimal endpoint representing a "functional cure", with or without anti-HBs seroconversion, since it indicates a significant suppression of HBV replication and viral protein expression [Block, 2017; Cornberg, 2017]. Currently, CHB patients have two main therapeutic options, with pegylated interferon alpha (PegIFNα) or with nucleoside / nucleotide analogues (NAs) [EASL, 2017]. PegIFNα, which aims to induce long-term immune control by a finite duration of treatment, can achieve sustained off-treatment control, but durable virologic responses and hepatitis B surface antigen (HBsAg) loss are limited to a small percentage of patients. Furthermore, a significant number of patients are ineligible for this type of treatment due to its poor tolerability and long-term safety concerns.
[0005] NAs act by suppressing DNA replication through inhibition of HBV polymerase reverse transcriptase activity. NAs approved in Europe for HBV treatment include entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), which are associated with a high barrier to HBV resistance, and lamivudine (LAM), adefovir dipivoxil (ADV) and telbivudine (TBV), which are associated with a low barrier to HBV resistance. The main advantages of treatment with potent NAs with a high barrier to resistance are their predictable high long-term antiviral efficacy leading to HBV DNA suppression in the majority of compliant patients, and their favorable safety profile. A disadvantage of NA treatment is its long-term treatment regimen, as NAs do not usually achieve HBV eradication and interruption of NAs can result in HBV recurrence [Kranidioti, 2015]. HBsAg loss, representing functional cure, is currently the gold standard treatment endpoint in CHB [Block, 2017; Cornberg, 2017], but is rarely achieved with NA treatment [Zoutendijk, 2011].
[0006] Due to the low rate of HBsAg seroclearance [Zoutendijk, 2011] and the high risk of off-NA viral relapse [Kranidioti, 2015], most patients are maintained on long-term or even indefinite NA therapy, which may be associated with poor patient compliance with therapy, increased financial costs, and increased risk of drug toxicity and drug resistance mutations due to long-term exposure [Terrault, 2015]. Therefore, new strategies to supplement NA therapy are needed to achieve a "functional cure" with a finite regimen.
[0007] New therapeutic strategies currently being explored include new antiviral strategies as well as novel immunotherapeutic strategies to boost HBV-specific adaptive immune responses or activate intrahepatic innate immunity [Durantel, 2016]. So far, none of these experimental treatments have been shown to be effective. Among the vaccination strategies evaluated, none have demonstrated robust polyfunctional CD8 expression against the HBV core antigen (HBcAg), which is crucial for restoring immune control against the virus. +Previous studies have failed to induce T cell responses [Lau, 2002; Li, 2011; Liang, 2011; Bertoletti, 2012; Boni, 2012]. Early efforts at recombinant vaccines based on HBV surface and / or preS antigens induced preliminary antibody responses but did not induce HBV-specific CD8+ T cell responses and did not provide clinical or virological benefit [Jung, 2002; Vandepapeliere, 2007]. DNA vaccines expressing the HBV envelope were unable to restore HBsAg and HBcAg-specific T cell responses and therefore did not reduce the risk of relapse in patients after NA cessation [Fontaine, 2015]. Using new delivery systems, DNA vaccines encoding S, pre-S1 / S2 (prime vaccine) and MVA viral vector vaccines (boost vaccine) did not show T cell induction or reduction in viremia, suggesting that HBV pre-S and surface antigens alone were not sufficient to cure patients [Cavenaugh, 2011]. More recently, vaccine strategies targeting multiple HBV antigens and new delivery systems have been investigated. Recombinant HBsAg / HBcAg vaccines resulted in a reduction in viral load to very low levels (i.e., approximately 50 IU / ml) in only half of the patients [Al-Mahtab, 2013]. DNA vaccines encoding S, pre-S1 / S2, core, polymerase and X proteins together with genetically adjuvanted IL-12 together with lamivudine induced multispecific T cell responses and a >2 log10 reduction in viral load in half of the patients. However, no change in quantitative detection of HBsAg, loss of HBsAg, or HBsAg seroconversion was observed in any patient [Yang, 2012].GS-4774 vaccine, a yeast-based T cell vaccine expressing HBV large S, core, and X proteins, did not result in a significant reduction of HBsAg in virally suppressed CHB patients [Lok, 2016]. Summary of the Invention [Problem to be solved by the invention]
[0008] There remains an unmet need for treatments that can clear HBsAg, allowing patients to safely discontinue NA therapy without virologic or clinical relapse. [Means for solving the problem]
[0009] Summary of the Invention In one aspect, a method of treating chronic hepatitis B infection (CHB) in a human comprises: a) administering to a human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. A method is provided, comprising:
[0010] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b), which in turn precedes step c). Optionally, step c) may be repeated. In another embodiment, step c) is performed simultaneously with step a) and / or step b).
[0011] Thus, in another aspect, there is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising: a) administering to a human i) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, concomitantly, ii) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc), and an adjuvant; and b) administering to the human: i) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, simultaneously, a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc) and an adjuvant. A method is provided, comprising:
[0012] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b). Optionally, step b) may be repeated.
[0013] In another aspect, there is provided an immunogenic combination for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic combination comprising: a) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) Compositions comprising recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B core antigen (HBc) and an adjuvant wherein the method comprises administering the compositions sequentially or simultaneously to a human.
[0014] In another aspect, an immunogenic composition is provided for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs), a nucleic acid encoding hepatitis B virus core antigen (HBc), and a nucleic acid encoding human invariant chain (hIi) fused to HBc, the method comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition. In certain embodiments, the immunogenic composition for use in the method of treating chronic CHB further comprises one or more recombinant HBV protein antigens.
[0015] In a further aspect, there is provided an immunogenic composition for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc), the method comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition. In a particular embodiment, the immunogenic composition for use in the method of treating chronic CHB further comprises one or more recombinant HBV protein antigens.
[0016] In a further aspect, there is provided an immunogenic composition for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a recombinant hepatitis B surface antigen (HBs), a C-terminally truncated recombinant hepatitis B virus core antigen (HBc), and an adjuvant comprising MPL (3-D monophosphoryl lipid A) and QS-21 (a triterpene glycoside purified from the bark of Quillaja saponaria), the method comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition. In certain embodiments, the immunogenic composition for use in the method of treating chronic CHB further comprises one or more vectors encoding one or more HBV antigens. [Brief description of the drawings]
[0017] [Figure 1] HBc-specific (A) and HBs-specific (B) CD8+ T cell responses 14 days after primary immunization with ChAd155-HBV (with and without hIi) and 7 days after MVA-HBV booster immunization (individual animals (with median values) are represented). [Diagram 2] HBc-specific antibody responses (individual animals (with geometric mean titers (GMT)) are shown) 14 days after primary immunization with ChAd155-HBV (with and without hIi) and 7 days after MVA-HBV booster immunization. [Diagram 3] HBc- and HBs-specific CD4+ T cell responses 7 days after the third dose of HBc, HBs or HBc-HBs formulated in NaCl, 50 μl AS01B-4 (pools of 5 animals / group (with median values) are represented). [Figure 4] HBs-specific CD8+ T cell responses 7 days after the third dose of HBc, HBs or HBc-HBs formulated in NaCl, 50 μl AS01B-4 (pools of 5 animals / group (with median values) are represented). [Diagram 5]Anti-HBc and anti-HBs antibody responses 14 days after the third dose of HBc, HBs or HBc-HBs formulated in NaCl, 50 μl of AS01B-4 (individual animals (with geometric means and 95% CI) are presented). [Figure 6A-B] HBs (A) and HBc (B)-specific CD4+ T cell responses 7 days after the third dose of NaCl, HBc-HBs, HBc-HBs and Alum, HBc-HBs and AS01B-4, or HBc-HBs and AS01E-4 (pools of 5 animals / group (with median values) are represented). [Figure 6C] HBs-specific CD8+(C) T cell responses 7 days after the third dose of NaCl, HBc-HBs, HBc-HBs and Alum, HBc-HBs and AS01B-4, or HBc-HBs and AS01E-4 (pools of 5 animals / group (with median values) are represented). [Figure 7] HBs (A) and HBc (B) specific antibody responses 14 days after the third dose of NaCl, HBc-HBs, HBc-HBs and Alum, HBc-HBs and AS01B-4, or HBc-HBs and AS01E-4 (individual animals (with geometric means and 95% CI) are shown). [Figure 8A] HBc(A)-specific CD8+ T cell responses (individual animals (with medians)) 7 days after the second and fourth doses of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 8B] HBs(B)-specific CD8+ T cell responses (individual animals (with medians)) 7 days after the second and fourth doses of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 9] HBc(A) or HBs(B)-specific CD4+ T cell responses (individual animals (with medians)) 7 days after the second and fourth doses of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 10] HBc- and HBs-specific CD4+ (A) and CD8+ (B) T cells among liver-infiltrating lymphocytes 7 days after the fourth dose of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein (pools of 3 or 4 animals (with medians)). [Figure 11] HBc-specific (A) and HBs-specific (B) antibody responses following a prime-boost vaccine regimen (individual animals (with geometric means) are represented). [Figure 12] mIi, HBc and HBs specific IFNγ ELISpot responses 2 weeks after the first and second injections of PBS or ChAd155-mIi-HBV vector (109 vp). [Figure 13] Anti-mIi antibody responses (ELISA) induced by two doses of ChAd155-mIi-HBV (109 vp) in CB6F1 mice, 2 weeks after the first and second injections. [Figure 14] HBc-specific splenic (A) or liver (B) CD8+ T cells (individual animals (with medians)) 7 days after the second and 7 days after the fourth dose of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 15] HBc-specific splenic (A) or liver (B) CD4+ T cells (individual animals (with medians)) 7 days after the second and 7 days after the fourth dose of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 16] HBs-specific splenic (A) or liver (B) CD8+ T cells (individual animals (with medians)) 7 days after the second and 7 days after the fourth dose of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 17]HBs-specific splenic (A) or liver (B) CD4+ T cells (individual animals (with medians)) 7 days after the second and 7 days after the fourth dose of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein. [Figure 18] Anti-HBs (A) and anti-HBc (B) binding antibody responses on days 23, 65, and 93 (before administration of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein, 7 days after the second dose, and 7 days after the fourth dose). [Figure 19] AST (A) and ALT (B) levels measured in serum of mice (groups 1, 2, 3 and 4) on days 38, 65 and 93 (7 days after the 1st, 2nd and 4th doses of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein, groups 1, 2, 3) or on day 93 (group 4). [Figure 20] HBs antigen levels in serum of AAV2 / 8-HBV-injected mice before administration of NaCl, heterologous vector prime-boost with subsequent recombinant protein, or heterologous vector prime-boost with simultaneous recombinant protein, 7 days after the second dose, and 7 days after the fourth dose. [Figure 21] Structure of the HBc-2A-HBs construct. [Figure 22] Structure of the hIi-HBc-2A-HBs construct. [Figure 23] Frequency of HBc- and HBs-specific CD4+ T cells in leukocytes of CB6F1 mice 7 days after the second immunization with adjuvanted HBc, HBs and different ratios of HBc / HBs. [Figure 24] Frequency of HBc- and HBs-specific CD4+ T cells in leukocytes of CB6F1 mice 7 days after the third immunization with adjuvanted HBc, HBs and various ratios of HBc / HBs. [Diagram 25]Frequency of HBs-specific CD8+ T cells in leukocytes of CB6F1 mice 7 days after the second and third immunizations with adjuvanted HBc, HBs and various ratios of HBc / HBs. [Figure 26] Anti-HBc and HBs humoral responses induced in CB6F1 mice 14 days after the second immunization with adjuvanted HBc, HBs and different ratios of HBc / HBs. [Figure 27] Anti-HBc and HBs humoral responses induced in CB6F1 mice 14 days after the third immunization with adjuvanted HBc, HBs and various ratios of HBc / HBs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Sequence Listing SEQ ID NO: 1: Amino acid sequence of HBs SEQ ID NO:2: Amino acid sequence of HBc truncation SEQ ID NO: 3: Amino acid sequence of the spacer incorporating the 2A cleavage region of the foot-and-mouth disease virus SEQ ID NO: 4: Nucleotide sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus SEQ ID NO: 5: Amino acid sequence of HBc-2A-HBs SEQ ID NO: 6: Nucleotide sequence encoding HBc-2A-HBs SEQ ID NO: 7: Amino acid sequence of hIi SEQ ID NO: 8: Nucleotide sequence encoding hIi SEQ ID NO: 9: Amino acid sequence of hIi-HBc-2A-HBs SEQ ID NO: 10: Nucleotide sequence encoding hIi-HBc-2A-HBs SEQ ID NO: 11: Amino acid sequence of HBc SEQ ID NO: 12: Amino acid sequence of hIi alternative variant SEQ ID NO: 13: Nucleotide sequence encoding hI alternative variant SEQ ID NO: 14: Alternative nucleic acid sequence of hIi-HBc-2A-HBs SEQ ID NO: 15: Alternative amino acid sequence of hIi-HBc-2A-HBs
[0019] Detailed Description of the Invention definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, the terms used herein are defined as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", Leuenberger, HGW, Nagel, B. and Klbl, H. eds. (1995), Helvetica Chimica Acta, CH-4010 Basel, Switzerland).
[0020] Throughout this specification and the claims which follow, unless the context requires otherwise, the words "comprise" and variations such as "comprises" and "comprising" are understood to mean the inclusion of a stated integer or step, or group of integers or steps, but not to exclude any other integer or step, or group of integers or steps.
[0021] Several documents are cited throughout the text of this specification. Each document cited herein (including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc.), whether supra or infra, is hereby incorporated by reference in its entirety. Nothing herein should be construed as an admission that the invention is not entitled to antedate disclosure by virtue of prior invention. All definitions provided herein with respect to one aspect of the invention also apply to other aspects of the invention.
[0022] The terms "protein," "polypeptide," and "peptide" are used interchangeably herein and refer to any peptide-linked chain of amino acids, regardless of length, co-translational, or post-translational modifications. A fusion protein (or "chimeric protein") is a recombinant protein that contains two or more peptide-linked proteins. A fusion protein is made by the joining of two or more genes that originally encoded separate proteins. Translation of the fusion genes results in a single fusion protein. With respect to a protein or polypeptide, recombinant means that the protein is expressed from a recombinant polynucleotide.
[0023] The terms "polynucleotide" and "nucleic acid" are used interchangeably herein and refer to a polymeric macromolecule made from nucleotide monomers. Suitably, the polynucleotides of the present invention are recombinant. By recombinant, it is meant that the polynucleotide is the product of at least one cloning, restriction or ligation step, or other procedure that results in a polynucleotide that is different from a polynucleotide found in nature.
[0024] A heterologous nucleic acid sequence refers to any nucleic acid sequence that is not isolated from, derived from, or based on a naturally occurring nucleic acid sequence found in a host organism. "Naturally occurring" means a sequence that is found in nature and has not been synthetically prepared or modified. A sequence is "derived" from a source if it has been isolated from the source but has been modified (e.g., by deletion, substitution (mutation), insertion, or other modification), suitably so as not to disrupt the normal function of the source gene.
[0025] Suitably, the polynucleotide used in the present invention is isolated. An "isolated" polynucleotide is one that is removed from its original environment. For example, a naturally occurring polynucleotide is isolated if it is separated from some or all of the coexisting materials in the natural system. A polynucleotide is considered to be isolated, for example, if it is cloned into a vector that is not part of its natural environment, or if it is contained in a cDNA.
[0026] The term "treating" as used herein with respect to chronic hepatitis B infection refers to the administration of a suitable composition with the intent of reducing symptoms of CHB, preventing the progression of CHB, or reducing the level of one or more detectable markers of CHB. The term "treating" should be interpreted accordingly. For example, preventing the progression of CHB may include preventing the onset of liver disease or stabilizing existing liver disease, as indicated by ALT (alanine transaminase) levels, liver fibrosis, or other suitable detectable markers. Other markers of CHB include serum HBV DNA levels, which are indicative of viral replication, and serum HBs antigen levels, which are indicative of viral load; thus, treating CHB may include reducing serum HBsAg (e.g., as determined by a quantitative immunoassay) or HBV DNA (e.g., as determined by the Cobas® HBV assay (Roche) or equivalent) levels to undetectable levels ("clearing" HBsAg or HBV DNA).
[0027] "Concurrent" administration, as used herein, refers to administration during the same ongoing immune response, and "concurrently" should be interpreted accordingly. Preferably, both components are administered at the same time (e.g., simultaneous administration of a composition comprising a vector and a composition comprising a protein), although one component can be administered within minutes (e.g., at the same medical appointment or physician's visit) or within hours of the other component. Such administration is also referred to as co-administration. Co-administration of separate components may be by the same route of administration, e.g., intramuscular injection. Alternatively, co-administration of separate components may be by different routes of administration, e.g., intramuscular and intradermal injection, intramuscular and intranasal administration, inhalation and subcutaneous administration, etc. In some embodiments, co-administration may refer to administration of an adenoviral vector and a protein component. In other embodiments, co-administration refers to administration of an adenoviral vector and another viral vector, e.g., a poxvirus, e.g., MVA. In other embodiments, co-administration refers to administration of an adenoviral vector and a protein component that is adjuvanted.
[0028] "Sequential" administration refers to administration of a first composition followed by administration of a second composition after a significant time. The period between two sequential administrations is 1 week to 12 months, for example, 2 weeks to 12 weeks, for example, 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks or 12 weeks, 6 months or 12 months. More specifically, it is 4 weeks to 8 weeks, for example, the period between sequential administrations may be 4 weeks. Thus, sequential administration encompasses the first administration and subsequent administrations in a prime-boost setting, i.e., when administration of the second composition is not performed during the ongoing immune response generated by the first administration.
[0029] An "immunogenic combination," as used herein, refers to multiple separately formulated immunogenic compositions that are administered sequentially and / or simultaneously in a single immunization regimen, e.g., a prime-boost regimen, where each separately formulated immunogenic composition is a component of the immunogenic combination.
[0030] With regard to percentage of homology, when looking at a pairwise alignment of two sequences, one can observe aligned identical residues ("identities") between the two sequences. The percentage of identity (or homology) can be calculated by (a) multiplying the quotient between the number of identities and the total length of the reference sequence by 100 (i.e., percentage of identity = (number of identities x 100) / length of reference sequence).
[0031] Regimen The present disclosure provides a novel method for the detection of potent CD8 + A vaccine regimen that provides a heterologous prime-boost schedule using two viral vectors encoding hepatitis B core (HBc) and hepatitis B surface (HBs) antigens to induce T cell responses, and that induces potent antigen-specific CD4 + The disclosed vaccine regimen involves the sequential or simultaneous administration of adjuvanted recombinant HBc and HBs proteins to induce T cell and antibody responses. The disclosed vaccine regimen induces HBs- and HBc-specific antibodies and CD8 T cells in a mouse model that recapitulates the virological and immunological characteristics of human chronic HBV infection, without the associated signs of hepatic alterations. + T cell responses and HBs-specific CD4 + T cell responses were successfully restored.
[0032] More specifically, a method of treating chronic hepatitis B infection (CHB) in a human, comprising: a) administering to a human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. A method is provided, comprising:
[0033] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b) and step b) preceding step c). Optionally, step c) may be repeated. In certain embodiments, the period between the steps of the method is 2-12 weeks, for example, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks or 12 weeks. In one embodiment, the period between the steps of the method is 4-8 weeks. In one embodiment, the period between the sequential administration of the composition according to the method is 4 weeks. In another embodiment, step c) is performed simultaneously with step a) and / or step b). In certain embodiments, simultaneous steps b) and c) may be repeated. In one embodiment, the steps of the method are performed sequentially, with step b) preceding step a) and step c) following step a) or performed simultaneously with step a) and / or step b). In one embodiment, the steps of the method are performed sequentially, with step c) preceding step a), which in turn precedes step b). In another embodiment, the steps of the method are performed sequentially, with step c) preceding step b), which in turn precedes step a). In a further embodiment, step c is repeated, with the steps of the method being performed in the following order: step a), step b), step c), step c). In a particular embodiment, the period between the steps of the method is 2-12 weeks, e.g., 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks. In one embodiment, the period between the steps of the method is 4-8 weeks. In one embodiment, the period between the sequential administration of the composition according to the method is 4 weeks.
[0034] In a particular embodiment, the composition administered in step a) of the method comprises a ChAd vector selected from the group consisting of ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan 5, Pan 6, Pan 7 (also called C7) and Pan 9, in particular ChAd63 or ChAd155. In a particular embodiment, the ChAd vector comprises a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of foot and mouth disease virus. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% homologous thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% homologous thereto). In certain embodiments, HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) is fused to hIi (e.g., SEQ ID NO: 7 or an amino acid sequence at least 98% homologous thereto, or SEQ ID NO: 12 or an amino acid sequence at least 98% homologous thereto). For example, HBc (e.g., SEQ ID NO: 11) is fused to hIi (e.g., SEQ ID NO: 7), or HBc (e.g., SEQ ID NO: 11) is fused to hIi (e.g., SEQ ID NO: 12). In certain embodiments, the composition administered in step a) of the method comprises a polynucleotide vector insert encoding hIi, HBc, 2A, and HBs, e.g., a ChAd155 vector comprising an insert encoding a construct having a structure shown in FIG. 22. In one embodiment, the composition administered in step a) of the method comprises a ChAd vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence of SEQ ID NO: 15. In certain embodiments, the composition administered in step a) of the method comprises a ChAd vector comprising a polynucleotide vector insert having the nucleotide sequence set forth in SEQ ID NO: 10 or the nucleotide sequence set forth in SEQ ID NO: 14. In one specific embodiment, the vector is a ChAd155 vector.Thus, in certain embodiments, the composition administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO:9. In other embodiments, the composition administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO:15. In one embodiment, the composition administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence as set forth in SEQ ID NO:10. In other embodiments, the composition administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence as set forth in SEQ ID NO:14.
[0035] In one embodiment, the composition administered in step b) of the method comprises an MVA vector comprising a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, the vector insert encodes HBc and HBs separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, the composition administered in step b) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding HBc, 2A and HBs, e.g., an insert encoding a construct having a structure as shown in FIG. 21. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% homologous thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% homologous thereto). In one embodiment, the composition administered in step b) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 5. In one embodiment, the composition administered in step b) of the method comprises an MVA vector comprising a polynucleotide vector insert having the nucleotide sequence shown in SEQ ID NO: 6.
[0036] In one embodiment, the composition administered in step c) of the method comprises recombinant HBc and recombinant HBs in a ratio of 1:1. In another embodiment, the ratio of HBc to HBs in the composition is greater than 1, for example, the ratio of HBc to HBs may be 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1 or more, especially 3:1 to 5:1, for example 3:1, 4:1 or 5:1, especially 4:1. In a particular embodiment, the composition administered in step c) of the method comprises recombinant HBc and recombinant HBs in a ratio of 4:1 or more. In a particular embodiment, the composition administered in step c) of the method comprises full-length recombinant Hepatitis B surface antigen (HBs) (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% homologous thereto), a C-terminally truncated recombinant Hepatitis B virus core antigen (HBc), and an adjuvant. In certain embodiments, the truncated recombinant HBc comprises the assembly domain of HBc, e.g., amino acids 1-149 of HBc (e.g., SEQ ID NO: 2 or an amino acid sequence at least 98% homologous thereto). In one embodiment, the composition administered in step c) of the method comprises full length recombinant HBs, amino acids 1-149 of HBc, and an adjuvant comprising MPL and QS-21. For example, the composition administered in step c) of the method comprises full length recombinant HBs (SEQ ID NO: 1), amino acids 1-149 of HBc (SEQ ID NO: 2), and an adjuvant comprising MPL and QS-21. In certain embodiments, the recombinant protein HBs and HBc antigens are in the form of virus-like particles.
[0037] In a further embodiment, there is provided a method of treating CHB in a human, comprising: a) administering to a human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); c) administering to the human a composition comprising a recombinant Hepatitis B surface antigen (HBs), a recombinant Hepatitis B core antigen (HBc) and an adjuvant; and d) administering to the human a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. A method is provided, comprising:
[0038] In another aspect of the invention, there is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising: a) administering to a human i) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, concomitantly, ii) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc), and an adjuvant; and b) administering to the human: i) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, simultaneously, a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc) and an adjuvant. A method is provided, comprising:
[0039] In one embodiment of this aspect of the invention, the method steps are performed sequentially, with step a) preceding step b). Optionally, step a) may be repeated. In one embodiment, the method steps are performed in the order of step a), followed by step a), followed by step b). In an alternative embodiment, the method steps are performed in the order of step a), followed by step b), followed by step a). Optionally, step b) may be repeated. In one embodiment, the method steps are performed in the order of step a), followed by step b), followed by step b). In an alternative embodiment, the method steps are performed in the order of step b), followed by step a), followed by step b). Optionally, step b) may be repeated two or more times. Optionally, both step a) and step b) may be repeated. In one embodiment of this aspect of the invention, the method steps are performed in the order of step a), followed by step b), followed by step b), followed by step b). In an alternative embodiment, the steps of the method are performed in the order of step b), followed by step a), followed by step b), followed by step b). In a further embodiment, the steps of the method are performed in the order of step a), followed by step a), followed by step b), followed by step b), optionally followed by step b). In a particular embodiment, the period between the steps of the method is 2 to 12 weeks, for example, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks. In one embodiment, the period between the steps of the method is 4 to 8 weeks. In one embodiment, the period between the sequential administration of the composition according to the method is 4 weeks.
[0040] Thus, in another embodiment of this aspect of the invention, there is provided a method of treating CHB in a human, comprising: a) administering to a human i) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc), and simultaneously ii) a composition comprising a recombinant Hepatitis B surface antigen (HBs), a recombinant Hepatitis B core antigen (HBc) and an adjuvant; b) administering to the human i) a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding an HBs antigen and a nucleic acid encoding an HBc antigen, and simultaneously ii) a composition comprising a recombinant HBs protein antigen, a recombinant HBc protein antigen and an adjuvant; c) administering to the human i) a composition comprising an MVA vector comprising a polynucleotide encoding an HBs antigen and a nucleic acid encoding an HBc antigen, and simultaneously ii) a composition comprising a recombinant HBs protein antigen, a recombinant HBc protein antigen and an adjuvant; and d) administering to the human i) a composition comprising an MVA vector comprising a polynucleotide encoding an HBs antigen and a nucleic acid encoding an HBc antigen, and simultaneously ii) a composition comprising a recombinant HBs protein antigen, a recombinant HBc protein antigen and an adjuvant. A method is provided, comprising:
[0041] In a particular embodiment, the time period between steps of the method is 2 to 12 weeks, for example, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks or 12 weeks. In one embodiment, the time period between steps of the method is 4 to 8 weeks. In one embodiment, the time period between sequential administrations of compositions according to the method is 4 weeks. In one embodiment, the composition i) administered in step a) of the method comprises a ChAd vector selected from the group consisting of ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan 5, Pan 6, Pan 7 (also called C7) and Pan 9, in particular ChAd63 or ChAd155. In a particular embodiment, the ChAd vector comprises a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of foot and mouth disease virus. In certain embodiments, the vector insert encodes HBc and HBs separated by a sequence encoding a spacer incorporating the 2A cleavage region of foot and mouth disease virus. In certain embodiments, HBc is fused to hIi. In certain embodiments, the composition i) administered in step a) of the method comprises a polynucleotide vector insert encoding hIi, HBc, 2A and HBs, e.g., a ChAd155 vector comprising an insert encoding a construct having a structure shown in FIG. 22. In certain embodiments, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% homologous thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% homologous thereto). In certain embodiments, HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) is fused to a hIi (e.g., SEQ ID NO: 7 or an amino acid sequence at least 98% homologous thereto, or SEQ ID NO: 12 or an amino acid sequence at least 98% homologous thereto). For example, HBc (e.g., SEQ ID NO: 11) is fused to a hIi (e.g., SEQ ID NO: 7), or HBc (e.g., SEQ ID NO: 11) is fused to a hIi (e.g., SEQ ID NO: 12). In one embodiment, the composition i) administered in step a) of the method comprises: The composition i) administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 9. In another embodiment, the composition i) administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 15. In one embodiment, the composition i) administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence as set forth in SEQ ID NO: 10. In another embodiment, the composition i) administered in step a) of the method comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence as set forth in SEQ ID NO: 14. In a particular embodiment, the composition ii) administered in step a) of the method comprises a full-length recombinant Hepatitis B surface antigen (HBs), a C-terminally truncated recombinant Hepatitis B core antigen (HBc), and an adjuvant. In a particular embodiment, the truncated recombinant HBc comprises the assembly domain of HBc, e.g., amino acids 1-149 of HBc. In one embodiment, the composition ii) administered in step a) of the method comprises full length recombinant HBs (e.g., SEQ ID NO: 1), amino acids 1-149 of HBc (e.g., SEQ ID NO: 2), and an adjuvant comprising MPL and QS-21. In a particular embodiment, the recombinant protein HBs and HBc antigens are in the form of virus-like particles.
[0042] In one embodiment, the composition i) administered in step b) of the method comprises an MVA vector comprising vector inserts encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% identical thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% identical thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% identical thereto). In a particular embodiment, the composition i) administered in step b) of the method comprises an MVA vector comprising polynucleotide vector inserts encoding HBc, 2A and HBs, e.g., an insert encoding a construct having the structure shown in Figure 21. In one embodiment, the composition i) administered in step b) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 5. In one embodiment, the composition i) administered in step b) of the method comprises an MVA vector comprising a polynucleotide vector insert having the nucleotide sequence shown in SEQ ID NO:6. In a particular embodiment, the composition ii) administered in step b) of the method comprises a full-length recombinant Hepatitis B surface antigen (HBs), a C-terminally truncated recombinant Hepatitis B virus core antigen (HBc), and an adjuvant. In a particular embodiment, the truncated recombinant HBc comprises the assembly domain of HBc, e.g., amino acids 1-149 of HBc. In one embodiment, the composition ii) administered in step b) of the method comprises a full-length recombinant HBs (e.g., SEQ ID NO:1), amino acids 1-149 of HBc (e.g., SEQ ID NO:2), and an adjuvant comprising MPL and QS-21. In a particular embodiment, the recombinant protein HBs and HBc antigens are in the form of virus-like particles.
[0043] In one embodiment, the composition i) administered in step c) of the method comprises an MVA vector comprising a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% identical thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% identical thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% identical thereto). In a particular embodiment, the composition i) administered in step c) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding HBc, 2A and HBs, e.g., an insert encoding a construct having the structure shown in Figure 21. In one embodiment, the composition i) administered in step c) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 5. In one embodiment, the composition i) administered in step c) of the method comprises an MVA vector comprising a polynucleotide vector insert having the nucleotide sequence shown in SEQ ID NO:6. In a particular embodiment, the composition ii) administered in step c) of the method comprises a full-length recombinant Hepatitis B surface antigen (HBs), a C-terminally truncated recombinant Hepatitis B virus core antigen (HBc), and an adjuvant. In a particular embodiment, the truncated recombinant HBc comprises the assembly domain of HBc, e.g., amino acids 1-149 of HBc. In a particular embodiment, the recombinant protein HBs and HBc antigen are in the form of a virus-like particle. In one embodiment, the composition ii) administered in step c) of the method comprises a full-length recombinant HBs (e.g., SEQ ID NO:1), amino acids 1-149 of HBc (e.g., SEQ ID NO:2), and an adjuvant comprising MPL and QS-21.
[0044] In one embodiment, the composition i) administered in step d) of the method comprises an MVA vector comprising a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% identical thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% identical thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% identical thereto). In a particular embodiment, the composition i) administered in step d) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding HBc, 2A and HBs, e.g., an insert encoding a construct having the structure shown in Figure 21. In one embodiment, the composition i) administered in step d) of the method comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 5. In one embodiment, the composition i) administered in step d) of the method comprises an MVA vector comprising a polynucleotide vector insert having the nucleotide sequence shown in SEQ ID NO:6. In a particular embodiment, the composition ii) administered in step d) of the method comprises a full-length recombinant Hepatitis B surface antigen (HBs), a C-terminally truncated recombinant Hepatitis B virus core antigen (HBc), and an adjuvant. In a particular embodiment, the truncated recombinant HBc comprises the assembly domain of HBc, e.g., amino acids 1-149 of HBc. In one embodiment, the composition ii) administered in step d) of the method comprises a full-length recombinant HBs (e.g., SEQ ID NO:1), amino acids 1-149 of HBc (e.g., SEQ ID NO:2), and an adjuvant comprising MPL and QS-21. In a particular embodiment, the recombinant protein HBs and HBc antigens are in the form of virus-like particles.
[0045] The present invention also provides a method for inducing a cellular and humoral immune response, in particular a CD4+ response, a CD8+ response and an antibody response, in a human with CHB, comprising: a) administering to a human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. The present invention provides a method comprising:
[0046] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b) which precedes step c). Optionally, step c) may be repeated. In another embodiment, step c) is performed simultaneously with step a) and / or step b). In a further embodiment, the method of inducing cellular and humoral immune responses, in particular CD4+ and CD8+ and antibody responses, in a human with CHB comprises: a) administering to a human i) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, concomitantly, ii) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc), and an adjuvant; and b) administering to the human: i) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, simultaneously, a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc) and an adjuvant. Includes.
[0047] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b). Optionally, step b) may be repeated.
[0048] The present invention also provides a method for reducing serum HBsAg levels and / or serum HBV DNA levels in a human with CHB, comprising: a) administering to a human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. The present invention provides a method comprising:
[0049] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b), which in turn precedes step c). Optionally, step c) may be repeated. In another embodiment, step c) is performed simultaneously with step a) and / or step b).
[0050] In a further embodiment, the method of reducing serum HBsAg levels and / or serum HBV DNA levels in a human with CHB comprises: a) administering to a human i) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, concomitantly, ii) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc), and an adjuvant; and b) administering to the human: i) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, simultaneously, a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc) and an adjuvant. Includes.
[0051] In one embodiment, the steps of the method are performed sequentially, with step a) preceding step b). Optionally, step b) may be repeated. In a further embodiment, the level of serum HBsAg is reduced to an undetectable level as determined by a quantitative immunoassay. In another embodiment, the level of serum HBV DNA is reduced to an undetectable level as determined by a Cobas® HBV assay or equivalent. In another embodiment, the level of serum HBsAg and / or the level of serum HBV DNA is reduced to an undetectable level and maintained for at least 6 months. In another embodiment, the level of serum HBsAg and / or the level of serum HBV DNA is reduced to an undetectable level and maintained and ALT levels are maintained within the normal range for at least 6 months.
[0052] antigen At least nine genotypes of HBV (A to I) have been identified, whose genomes differ by more than 8%. Within a given HBV genotype, multiple genosubtypes have been identified that differ by 4-8%. Antigens for use in the disclosed methods are suitably selected to provide immunological coverage across multiple, preferably all, HBV genotypes. Hepatitis B core protein antigen (HBc) is highly conserved across genotypes and genosubtypes, and Hepatitis B surface protein antigen (HBs) sequences are suitably selected to contain important cross-genotype-preserved B-cell epitopes that allow for the induction of a broad neutralizing response. Suitably, HBc and HBs sequences for use in the disclosed methods and compositions are based on those from genotype / subtype A2.
[0053] Suitably, HBs antigen for use in the disclosed methods and compositions is derived from small, medium or large surface antigen proteins. In particular, suitable HBs antigens include the small (S) protein of HBV adw2 strain, genotype A. For example, a suitable HBs antigen has the 226 amino acid sequence SEQ ID NO: 1. When used as a recombinant protein, the HBs antigen is preferably associated with a virus-like particle. This antigen is included in well-studied commercial hepatitis B preventive vaccines (Engerix B, Fendrix, Twinrix and others) and has been demonstrated to be protective against hepatitis B across genotypes. Preferably, recombinant HBs protein antigen is expressed from yeast and purified for use in the vaccine compositions and methods of the invention. Suitable methods for expression and purification are known, for example from EP1307473B1.
[0054] Hepatitis B core protein (HBc) is the major component of the nucleocapsid shell that packages the viral genome. This protein (183-185 amino acids long) is expressed in the cytoplasm of infected cells and remains unglycosylated. HBc contains a 149 residue assembly domain and a 34-36 residue RNA binding domain (at the C-terminus). HBc antigens for use in the disclosed methods and compositions may be full length or C-terminally truncated proteins (lacking the RNA binding C-terminus), e.g., 145-149 amino acids of the assembly domain of wild-type core antigen protein, e.g., amino acids 1-145, 1-146, 1-147, 1-148 or amino acids 1-149 of wild-type Hepatitis B core antigen protein. The truncated proteins retain the ability to assemble into nucleocapsid particles. HBc antigens suitable for use in the disclosed methods and compositions have an amino acid sequence derived from HBV adw2 strain, genotype A. When used as a recombinant protein, the HBc antigen is suitably truncated from the wild type at the C-terminus, in particular the antigen may have the amino acid sequence of SEQ ID NO: 2. Preferably, the recombinant HBc protein antigen is expressed from E. coli and purified for use in the vaccine compositions and methods of the invention. Methods for recombinant expression of viral proteins in E. coli are well known in the art.
[0055] When used as a recombinant protein, the HBc antigen is preferably associated with a virus-like particle. When expressed from a viral vector, the HBc antigen may be full-length or truncated, for example, suitably full-length HBc antigen (e.g., SEQ ID NO: 11). Suitable doses of recombinant HBs antigen for use in the methods disclosed herein are from 10 μg per administration to 100 μg per administration, for example, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, or 100 μg per administration. Suitable doses of recombinant HBc antigen for use in the methods disclosed herein are from 10 μg per administration to 100 μg per administration, for example, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, or 100 μg per administration.
[0056] Antigens are substances that induce immune responses in the body, especially the production of antibodies. Antigens can be foreign, i.e. of pathogenic origin, or derived from the organism itself, the latter being called self or auto antigens. Antigens can be presented on the surface of antigen-presenting cells by MHC molecules. There are two classes of MHC molecules, MHC class I (MHC-I) and MHC class II (MHC-II). MHC-II molecules are membrane-bound receptors that are synthesized in the endoplasmic reticulum and leave the endoplasmic reticulum in the MHC class II compartment. To prevent endogenous peptides, i.e. self antigens, from binding to MHC-II molecules and being presented to generate an immune response, the nascent MHC-II molecule binds to another protein, the invariant chain, which blocks the peptide-binding groove of the MHC-II molecule. The human invariant chain (hIi, also known as CD74 when expressed on the plasma membrane) is an evolutionarily conserved type II membrane protein with several roles within cells and throughout the immune system [Borghese, 2011]. When MHC class II compartments fuse with late endosomes containing phagocytosed and degraded foreign proteins, the invariant chain is cleaved, leaving only the CLIP region bound to MHC-II molecules. In a second step, CLIP is removed by HLA-DM molecules, leaving MHC-II molecules free to bind fragments of foreign proteins. Once the MHC class II compartment fuses with the plasma membrane, the fragments are presented on the surface of antigen-presenting cells, thus presenting foreign antigens to other cells, mainly T helper cells.
[0057] It is known that when adenoviral expression systems encoding a fusion of the invariant chain and an antigen are used for vaccination, the immune response to the antigen is increased (see WO2007 / 062656 (also published as US2011 / 0293704, incorporated by reference for the purposes of disclosing the invariant chain sequence)), i.e., the invariant chain enhances the immunogenicity of the antigen, and invariant chains such as hIi are sometimes referred to as "genetic adjuvants" in recognition of this effect. Moreover, the adenoviral constructs have been found to be useful for priming immune responses in the context of prime-boost vaccination regimens (see WO2014 / 141176 (also published as US2016 / 0000904); and WO2010 / 057501 (also published as US2010 / 0278904, which is incorporated by reference for the purposes of disclosing invariant chain sequences and adenoviral vectors encoding invariant chain sequences)). In particular, the hIi sequence and hIi are intended to stimulate the expression of CD8 + It has the potential to increase T cell responses [Spencer, 2014; Capone, 2014]. In certain embodiments, the nucleotide sequence included in the vector for use in the methods, uses and compositions disclosed herein may include a nucleotide sequence encoding a hIi. The amino acid sequence for hIi that may be included in the disclosed adenoviral vector ChAd155-hIi-HBV is shown in SEQ ID NO:7, and an alternative sequence is shown in SEQ ID NO:12. Nucleotide sequences encoding these amino acid sequences are shown in SEQ ID NO:8 and SEQ ID NO:13. Suitably, the nucleotide sequence encoding the hIi is fused to a nucleotide sequence encoding HBc antigen to generate a fusion protein in which the hIi polypeptide is fused N-terminally to the HBc antigen.
[0058] vector In addition to a polynucleotide encoding an antigen protein (also referred to herein as an "insert"), vectors for use in the methods and compositions disclosed herein may also contain conventional control elements operably linked to the encoding polynucleotide to permit transcription, translation and / or expression in a cell transfected with the vector. Thus, the vector insert polynucleotide encoding the protein antigen is incorporated into an expression cassette with appropriate control elements.
[0059] Expression control elements include appropriate transcription initiation, termination, promoter, and enhancer sequences; efficient RNA processing signals, such as splicing and polyadenylation (polyA) signals, e.g., rabbit β-globin polyA; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., Kozak consensus sequences); sequences that enhance protein stability; and, if desired, sequences that enhance secretion of the encoded product.
[0060] A promoter is a nucleotide sequence that allows the binding of RNA polymerase and directs the transcription of a gene. Typically, promoters are located in the 5' non-coding region of a gene, proximal to the transcription start site of the gene. Sequence elements within a promoter that function in the initiation of transcription are often characterized by consensus nucleotide sequences. Examples of promoters include, but are not limited to, promoters from bacteria, yeast, plants, viruses, and mammals (including humans). Numerous expression control sequences, e.g., endogenous, native, constitutive, inducible, and / or tissue-specific promoters, are known in the art and may be utilized.
[0061] Examples of constitutive promoters include the TBG promoter, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer, see, e.g., Boshart et al, Cell, 41:521-530 (1985)), the CASI promoter, the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1a promoter (Invitrogen). Suitably, the promoter is a CMV promoter or a variant thereof, more suitably a human CMV (HCMV) promoter or a variant thereof.
[0062] Adenovirus Vectors Adenoviruses are widely used for gene transfer applications due to their ability to achieve highly efficient gene transfer in various target tissues and their large transgene carrying capacity. Usually, the E1 gene of adenovirus is deleted and replaced with a transgene cassette consisting of a selected promoter, a cDNA sequence of the gene of interest, and a polyA signal, resulting in a replication-deficient recombinant virus. Human adenovirus vectors have been shown to mediate CD8 expression to transgenes in animal models and in humans. +It has been shown to be a powerful vector for the induction of T cell responses. Adenoviruses have a broad tropism and the ability to infect replicating and non-replicating cells. The main limitation of the clinical application of vectors based on human adenoviruses is the high prevalence of neutralizing antibodies in the general population. Adenoviruses isolated from alternative species are considered as potential vaccine vectors to circumvent the problem of pre-existing anti-adenovirus immunity in humans. Among them, simian adenoviruses derived from chimpanzees, gorillas or bonobos may be suitable for use in delivering antigens and in eliciting targeted T cell and / or humoral responses against those antigens in humans. Simian adenoviruses, such as those derived from chimpanzees, have been tested in clinical studies. Chimpanzee adenoviral vectors have low / no seroprevalence in human populations, are not known to cause pathological disease in humans, and some ChAd vectors can be grown to high titers in cell lines previously used to generate clinical grade material, e.g., human embryonic kidney 293 (HEK293).
[0063] A replication-incompetent or replication-deficient adenovirus is an adenovirus that is unable to replicate because it has been engineered to contain at least a functional deletion (or "loss-of-function" mutation), i.e., a deletion or mutation that impairs the function of a gene without completely removing the gene, such as the introduction of an artificial stop codon, a deletion or mutation of an active site or interaction domain, a mutation or deletion of a regulatory sequence of a gene, or the like, or the complete removal of a gene that encodes a gene product that is essential for viral replication (e.g., one or more of the adenoviral genes selected from E1A, E1B, E2A, E2B, E3, and E4 (e.g., E3 ORF1, E3 ORF2, E3 ORF3, E3 ORF4, E3 ORF5, E3 ORF6, E3 ORF7, E3 ORF8, E3 ORF9, E4 ORF7, E4 ORF6, E4 ORF5, E4 ORF4, E4 ORF3, E4 ORF2, and / or E4 ORF1). Suitably, the E1 and E3 genes are deleted, more suitably, the E1, E3 and E4 genes are deleted.
[0064] Suitable vectors for use in the methods and compositions disclosed herein are replication-deficient chimpanzee adenovirus vectors, such as ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan 5, Pan 6, Pan 7 (also called C7), or Pan 9. Examples of such strains are described in WO03 / 000283, WO2005 / 071093, WO2010 / 086189, and WO2016 / 198621. The ChAd155 vector (see WO2016 / 198621, which is incorporated by reference for purposes of disclosing the ChAd155 vector sequence and methods) belongs to the same phylogenetic adenovirus group (group C) as the ChAd3 vector. In one embodiment, the vector for use in the methods and compositions disclosed herein is a ChAd vector of phylogenetic group C, such as ChAd3 or ChAd155. In one specific embodiment, the method of treating chronic hepatitis B disclosed herein comprises administering to a human a composition comprising a ChAd155 vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs) and a nucleic acid encoding hepatitis B virus core antigen (HBc). A suitable dose of ChAd vector for use in the methods disclosed herein is 1×10 per administration. 8 ~1×10 11 Viral particles (vp), e.g., about 1 x 10 per dose 8 , 5×10 8 , 1×10 9 , 5×10 9 , 1×10 10 , 5×10 10 Or 1×10 11 The virus particle (vp).
[0065] More specifically, in one embodiment, the vector for use in the methods and compositions disclosed herein is a replication-deficient chimpanzee adenoviral vector ChAd155 that encodes a fusion of sequences derived from two HBV proteins: HBc (core, nucleocapsid protein) and HBs (small surface antigen). In a particular specific embodiment, the vector is ChAd155 that encodes HBc and HBs separated by SEQ ID NO:3 (resulting in a 23 amino acid tail at the C-terminus of the upstream protein and a single proline at the N-terminus of the downstream protein), a spacer that incorporates sequences encoding the 2A cleavage region of the foot and mouth disease virus (FMDV) [Donnelly et al. 2001] for processing HBc and HBs into separate proteins. Cleavage of the core from the surface antigen allows proper folding of HBs and allows the generation of an antibody response against the surface antigen. Alternatively, the adenoviral vector may be a dual promoter (bicistronic) vector that allows independent expression of HBs and HBc antigens.
[0066] In certain embodiments, the N-terminal portion of the gene encoding the HBc protein may be fused to a gene encoding the human major histocompatibility complex (MHC) class II binding invariant chain p35 isoform (i.e., hIi or CD74). Thus, certain ChAd155 vectors for use in the methods and compositions disclosed herein include a polynucleotide vector insert encoding a construct having the structure shown in FIG. 22, including hIi, HBc, 2A, and HBs. The amino acid sequence of such a construct is set forth in SEQ ID NO:9, and the nucleotide sequence encoding the amino acid sequence of the construct is set forth in SEQ ID NO:10. The amino acid sequence of an alternative such construct is set forth in SEQ ID NO:15, and the nucleotide sequence encoding the amino acid sequence of the construct is set forth in SEQ ID NO:14.
[0067] Modified vaccinia virus Ankara (MVA) vector Modified vaccinia virus Ankara (MVA) is replication-deficient in humans and other mammals and is derived from vaccinia virus. It belongs to the Poxvirus family and was initially developed to improve the safety of smallpox vaccination by passage of vaccinia virus in chicken embryo fibroblasts (CEF) over 570 times, which resulted in multiple deletions, after which the virus was highly attenuated and replication-deficient in humans and other mammals. The replication deficiency occurs late in virion assembly so that viral and recombinant gene expression is not compromised, making MVA an efficient single-round expression vector that cannot cause infection in mammals. MVA has since been widely used as a viral vector to induce antigen-specific immunity against transgenes in both animal models and humans. A description of MVA can be found in Mayr A, et.al. (1978) and Mayr, A., et.al. (1975).
[0068] In one embodiment, the MVA is derived from virus seed batch 460 MG obtained from the 571st passage of vaccinia virus on CEF cells. In another embodiment, the MVA is derived from virus seed batch MVA 476 MG / 14 / 78. In a further embodiment, the MVA was derived or produced before December 31, 1978 and is free of prion contamination. A suitable dose of MVA vector for use in the methods disclosed herein is 1×10 per administration. 6 ~1×10 9 Plaque forming units (pfu), e.g., about 1 x 10 per dose 6 , 2×10 6 , 5×10 6 , 1×10 7 , 2×10 7 , 5×10 7 , 1×10 8 , 2×10 8 , 5×10 8 Or 1×10 9 It is pfu.
[0069] In one specific embodiment, the method of treating chronic hepatitis B disclosed herein comprises administering to a human a composition comprising an MVA vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs) and a nucleic acid encoding hepatitis B virus core antigen (HBc).
[0070] More specifically, in one embodiment, a vector for use in the methods and compositions disclosed herein is an MVA encoding a fusion of sequences derived from two HBV proteins: HBc (core nucleocapsid protein) and HBs (small surface antigen). In a particular embodiment, a vector for use in the methods and compositions disclosed herein is an MVA encoding HBc and HBs separated by a spacer SEQ ID NO:3 (resulting in a 23 amino acid tail at the C-terminus of the upstream protein and a single proline at the N-terminus of the downstream protein) that incorporates sequences encoding the 2A cleavage region of the foot and mouth disease virus for processing HBc and HBs into separate proteins. Thus, a particular MVA vector for use in the methods and compositions disclosed herein comprises a polynucleotide vector insert encoding a construct having the structure shown in FIG. 21, including HBc, 2A and HBs. The amino acid sequence of such a construct is set forth in SEQ ID NO:5, and the nucleotide sequence encoding the amino acid insert construct is set forth in SEQ ID NO:6.
[0071] Pharmaceutical Compositions In certain embodiments, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method of treating CHB comprises a ChAd vector selected from the group consisting of ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan 5, Pan 6, Pan 7 (also referred to as C7), and Pan 9, in particular ChAd63 or ChAd155. In certain embodiments, the ChAd vector comprises a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of foot and mouth disease virus. In certain embodiments, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% homologous thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% homologous thereto). In certain embodiments, HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) is fused to hIi (e.g., SEQ ID NO: 7 or an amino acid sequence at least 98% homologous thereto, or SEQ ID NO: 12 or an amino acid sequence at least 98% homologous thereto). For example, HBc (e.g., SEQ ID NO: 11) is fused to hIi (e.g., SEQ ID NO: 7), or HBc (e.g., SEQ ID NO: 11) is fused to hIi (e.g., SEQ ID NO: 12). In certain embodiments, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method of treating CHB comprises a ChAd vector comprising a polynucleotide vector insert encoding hIi, HBc, 2A, and HBs, e.g., an insert encoding a construct having a structure shown in FIG. 22. In one embodiment, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method of treating CHB comprises a ChAd vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 9 or the amino acid sequence of SEQ ID NO: 15.In certain embodiments, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method for treating CHB comprises a ChAd vector comprising a polynucleotide vector insert having the nucleotide sequence set forth in SEQ ID NO: 10 or the nucleotide sequence set forth in SEQ ID NO: 14. In one specific embodiment, the vector is a ChAd155 vector. Thus, in certain embodiments, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method for treating CHB comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 9. In other embodiments, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method for treating CHB comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 15. In one embodiment, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method for treating CHB comprises a ChAd155 vector comprising a polynucleotide vector insert having the nucleotide sequence set forth in SEQ ID NO: 10. In other embodiments, a composition comprising a replication-deficient chimpanzee adenoviral vector for use in a method of treating CHB comprises a ChAd155 vector comprising a polynucleotide vector insert having the nucleotide sequence set forth in SEQ ID NO:14.
[0072] In one embodiment, a composition comprising an MVA vector for use in a method of treating CHB comprises an MVA vector comprising a vector insert encoding HBc and HBs separated by a sequence encoding the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, the vector insert encodes HBc and HBs separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus. In a particular embodiment, a composition comprising an MVA vector for use in a method of treating CHB comprises an MVA vector comprising a polynucleotide vector insert encoding HBc, 2A and HBs, e.g., an insert encoding a construct having a structure as shown in FIG. 21. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO: 11 or an amino acid sequence at least 98% homologous thereto) and HBs (e.g., SEQ ID NO: 1 or an amino acid sequence at least 98% homologous thereto) separated by a sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus (e.g., SEQ ID NO: 3 or an amino acid sequence at least 98% homologous thereto). In one embodiment, a composition comprising an MVA vector for use in a method of treating CHB comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 5. In one embodiment, a composition comprising an MVA vector for use in a method of treating CHB comprises an MVA vector comprising a polynucleotide vector insert having the nucleotide sequence shown in SEQ ID NO: 6.
[0073] In one embodiment, a composition comprising a recombinant HBs antigen, a recombinant HBc antigen and an adjuvant for use in a method for treating CHB comprises recombinant HBc and recombinant HBs in a ratio of 1:1. In another embodiment, the ratio of HBc to HBs in the composition is greater than 1, for example, the ratio of HBc to HBs may be 1.5:1, 2:1, 2.5:1, 3:1, 3.5:1, 4:1, 4.5:1, 5:1, 5.5:1, 6:1 or more, especially a ratio of 3:1 to 5:1, such as 3:1, 4:1 or 5:1, especially 4:1. In a particular embodiment, a composition comprising a recombinant HBs antigen, a recombinant HBc antigen and an adjuvant for use in a method for treating CHB comprises recombinant HBc and recombinant HBs in a ratio of 4:1 or more. In certain embodiments, a composition comprising recombinant HBs antigen, recombinant HBc antigen and an adjuvant for use in a method of treating CHB comprises full length recombinant hepatitis B surface antigen (HBs) (e.g., SEQ ID NO: 1), a C-terminally truncated recombinant hepatitis B core antigen (HBc), and an adjuvant. In certain embodiments, the truncated recombinant HBc comprises the assembly domain of HBc, e.g., amino acids 1-149 of HBc (e.g., SEQ ID NO: 2). In one embodiment, a composition comprising recombinant HBs antigen, recombinant HBc antigen and an adjuvant for use in a method of treating CHB comprises full length recombinant HBs, amino acids 1-149 of HBc, and an adjuvant comprising MPL and QS-21. For example, a composition comprising recombinant HBs antigen, recombinant HBc antigen and an adjuvant for use in a method of treating CHB comprises full length recombinant HBs (SEQ ID NO: 1), amino acids 1-149 of HBc (SEQ ID NO: 2), and an adjuvant comprising MPL and QS-21. In a specific embodiment, the recombinant protein HBs and HBc antigens are in the form of virus-like particles.
[0074] The compositions disclosed herein find use in the disclosed methods and are suitably pharma- ceutically acceptable compositions. Suitably, a pharmaceutical composition includes a pharma- ceutically acceptable carrier.
[0075] Compositions containing ChAd or MVA vectors may be prepared for administration by a pharma- ceutical or physiologically acceptable carrier, such as a suspension of viral vector particles in isotonic saline or other isotonic salt solution. Suitable carriers will be apparent to those skilled in the art and will depend in large part on the route of administration.
[0076] Compositions containing recombinant protein antigens may be prepared by isolation and purification of the proteins from cell cultures in which they are expressed, suspension in a formulation buffer containing one or more salts, surfactants and / or cryoprotectants, and lyophilized. For example, a suitable formulation buffer may contain a sugar or mixture of sugars, such as sucrose, trehalose or sucralose, as a cryoprotectant, and a non-ionic copolymer, such as poloxamer, as a surfactant. For administration, the lyophilized recombinant protein formulation is reconstituted in a pharma- ceutically or physiologically acceptable carrier, such as an isotonic saline or other isotonic salt solution for injection or inhalation. Suitable carriers will be apparent to those skilled in the art and will depend largely on the route of administration. The reconstituted composition may also contain an adjuvant, or a mixture of adjuvants. In one embodiment, the lyophilized recombinant protein is reconstituted in a liquid adjuvant-based formulation.
[0077] The term "carrier" as used herein refers to a pharmacologically inert substance, such as, but not limited to, a diluent, excipient, or vehicle with which a therapeutically active ingredient is administered. Liquid carriers include, but are not limited to, sterile liquids, such as saline solutions in water and oils, such as those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Saline solutions and aqueous dextrose and glycerol solutions can also be used as liquid carriers, particularly for injectable solutions. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin.
[0078] The compositions for use in the methods disclosed herein may include an adjuvant system in addition to the vector or recombinant protein of the composition. The term "adjuvant" refers to an agent that increases, stimulates, activates, enhances, or modulates the immune response to the antigen of the composition, either at the cellular or humoral level, for example, an immunological adjuvant stimulates the immune system's response to an antigen(s) but does not have an immunological effect by itself. The compositions disclosed herein may include an adjuvant as a separate component in the formulation, regardless of whether the vector included in the composition also codes for a "genetic adjuvant" such as hIi.
[0079] A suitable adjuvant is one that can enhance immune response in subjects with chronic conditions and destroyed immune capabilities. CHB patients are characterized by an inability to mount efficient innate and adaptive immune responses against viruses, which makes efficient vaccine development difficult. In these patients, one important function of adjuvanted vaccine formulations should be to target cellular immune response toward T helper 1 (Th1) profile, which is recognized as important for the elimination of intracellular pathogens.
[0080] Examples of suitable adjuvants include, but are not limited to, inorganic adjuvants (e.g., inorganic metal salts, such as aluminum phosphate or aluminum hydroxide), organic non-peptide adjuvants (e.g., saponins, such as QS21, or squalene), oil-based adjuvants (e.g., Freund's complete and incomplete adjuvants), cytokines (e.g., IL-1β, IL-2, IL-7, IL-12, IL-18, GM-CFS, and INF-γ), particulate adjuvants (e.g., immune stimulating complex (IFN-γ)), and / or soluble adjuvants (e.g., soluble adjuvants such as ... Examples of adjuvants include ISCOMS, liposomes, or biodegradable microspheres), virosomes, bacterial adjuvants (e.g., monophosphoryl lipid A (MPL), e.g., 3-de-O-acylated monophosphoryl lipid A (3D-MPL), or muramyl peptides), synthetic adjuvants (e.g., non-ionic block copolymers, muramyl peptide analogs, or synthetic lipid A), synthetic polynucleotide adjuvants (e.g., polyarginine or polylysine), and immunostimulatory oligonucleotides containing unmethylated CpG dinucleotides ("CpG"). In particular, the adjuvant may be an organic non-peptide adjuvant (e.g., a saponin, e.g., QS21, or squalene) and / or a bacterial adjuvant (e.g., monophosphoryl lipid A (MPL), e.g., 3-de-O-acylated monophosphoryl lipid A (3D-MPL)).
[0081] One suitable adjuvant is monophosphoryl lipid A (MPL), in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL). Chemically, it is often supplied as a mixture of 3-de-O-acylated monophosphoryl lipid A with 4, 5, or 6 acylated chains. It can be purified and prepared by the methods taught in GB 2122204B, which also discloses the preparation of diphosphoryl lipid A and its 3-O-deacylated variant. Other purified and synthetic lipopolysaccharides have been described [U.S. Patent No. 6,005,099 and EP0729473B1; Hilgers, 1986; Hilgers, 1987; and EP0549074B1].
[0082] Saponins are also suitable adjuvants [Lacaille-Dubois, 1996]. For example, the saponin Quil A (derived from the bark of the South American tree Quillaja saponaria Molina) and fractions thereof are described in US Patent No. 5,057,540 and Kensil, 1996; and EP 0 362 279 B1. Purified fractions of Quil A, such as QS21 and QS17, are also known as immunostimulants; methods for their production are disclosed in US Patent No. 5,057,540 and EP 0 362 279 B1. The use of QS21 is further described in Kensil, 1991. Combinations of QS21 with polysorbates or cyclodextrins are also known (WO 99 / 10008). Particulate adjuvant systems comprising fractions of Quil A, such as QS21 and QS7, are described in WO 96 / 33739 and WO 96 / 11711.
[0083] Adjuvants such as those mentioned above may be formulated with carriers such as liposomes, oil-in-water emulsions, and / or metal salts (including aluminium salts such as aluminium hydroxide). For example, 3D-MPL may be formulated with aluminium hydroxide (EP 0 689 454) or an oil-in-water emulsion (WO 95 / 17210); QS21 may be formulated with cholesterol-containing liposomes (WO 96 / 33739), an oil-in-water emulsion (WO 95 / 17210) or alum (WO 98 / 15287).
[0084] Combinations of adjuvants may also be utilized in the disclosed compositions, particularly combinations of monophosphoryl lipid A and saponin derivatives (see, for example, WO 94 / 00153; WO 95 / 17210; WO 96 / 33739; WO 98 / 56414; WO 99 / 12565; WO 99 / 11241), more particularly the combination of QS21 and 3D-MPL as disclosed in WO 94 / 00153, or compositions in which QS21 is quenched in cholesterol-containing liposomes (DQ) as disclosed in WO 96 / 33739. A potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil-in-water emulsion is described in WO 95 / 17210 and is another formulation that may find use in the disclosed compositions. Thus, suitable adjuvant systems include, for example, monophosphoryl lipid A, preferably 3D-MPL, in combination with an aluminum salt (e.g., as described in WO00 / 23105). Further exemplary adjuvants include QS21 and / or MPL and / or CpG. As disclosed in WO96 / 33739, QS21 may be quenched in cholesterol-containing liposomes.
[0085] Thus, a suitable adjuvant for use in the disclosed compositions is AS01, a liposome-based adjuvant containing MPL and QS-21. Liposomes are vehicles for the MPL and QS-21 immune enhancers and are composed of dioleoylphosphatidylcholine (DOPC) and cholesterol in a phosphate buffered saline solution. AS01 B-4 is a particularly preferred variant of the AS01 adjuvant and is composed of the immune enhancer QS-21 (a triterpene glycoside purified from the bark of Quillaja saponaria) and MPL (3-D monophosphoryl lipid A) in PBS solution, together with DOPC / cholesterol liposomes and sorbitol as a vehicle for the immune enhancer. B-4 A single human dose (0.5 mL) of AS01 contains 50 μg of QS-21 and 50 μg of MPL.E-4 is AS01 B-4 This corresponds to a 2-fold dilution of QS-21 and 25 μg of MPL per human dose.
[0086] In one embodiment, there is provided an immunogenic combination for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic combination comprising a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. In one embodiment, the immunogenic combination comprises a composition comprising recombinant Hepatitis B surface antigen (HBs), truncated recombinant Hepatitis B core antigen (HBc) and an adjuvant. In one embodiment, the immunogenic combination comprises a composition comprising recombinant HBs, truncated recombinant HBc and AS01 adjuvant. In a particular embodiment, the immunogenic combination comprises a ratio of truncated recombinant HBc and recombinant HBs of 4:1 or greater, and an AS01 adjuvant, e.g., AS01 B-4 Or AS01 E-4 The composition includes:
[0087] In one embodiment, there is provided an immunogenic combination for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic combination comprising: a) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) Compositions comprising recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B core antigen (HBc) and an adjuvant wherein the method comprises administering the compositions sequentially or simultaneously to a human.
[0088] In another aspect, an immunogenic composition is provided for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs), a nucleic acid encoding hepatitis B core antigen (HBc), and a nucleic acid encoding human invariant chain (hIi) fused to HBc, the method comprising administering the composition in a prime-boost regimen with at least one other immunogenic composition. In one embodiment, the composition comprises a ChAd vector selected from the group consisting of ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan 5, Pan 6, Pan 7 (also referred to as C7), and Pan 9, in particular ChAd63 or ChAd155. In certain embodiments, the ChAd vector comprises vector inserts encoding HBc and HBs separated by a spacer incorporating a sequence encoding the 2A cleavage region of foot and mouth disease virus. In certain embodiments, the composition comprises a ChAd155 vector comprising polynucleotide vector inserts encoding hIi, HBc, 2A, and HBs, e.g., an insert encoding a construct having a structure as shown in FIG. 22. In one embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO:9. In another embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO:15. In one embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence as shown in SEQ ID NO:10. In another embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence as shown in SEQ ID NO:14.
[0089] In a further aspect, an immunogenic composition is provided for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc), the method comprising administering the composition in a prime-boost regimen with at least one other immunogenic composition. In one embodiment, the composition comprises an MVA vector comprising vector inserts encoding HBc and HBs separated by a spacer incorporating a sequence encoding the 2A cleavage region of foot and mouth disease virus. In a particular embodiment, the composition comprises an MVA vector comprising polynucleotide vector inserts encoding HBc, 2A and HBs, e.g., an insert encoding a construct having a structure as shown in FIG. 21. In one embodiment, the composition comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO:5. In one embodiment, the composition comprises an MVA vector comprising a polynucleotide vector insert having a nucleotide sequence as shown in SEQ ID NO:6.
[0090] In a further aspect, an immunogenic composition is provided for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a recombinant hepatitis B surface antigen (HBs), a C-terminal truncated recombinant hepatitis B core antigen (HBc), and an adjuvant comprising MPL and QS-21, the method comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition. In one embodiment, the composition comprises a truncated recombinant HBc comprising the assembly domain of HBc, e.g., amino acids 1-149 of HBc. In one embodiment, the composition comprises full length recombinant HBs, amino acids 1-149 of HBc, and an adjuvant comprising MPL and QS-21. More specifically, a composition for use in a method of treating chronic hepatitis B infection (CHB) in a human comprises full-length recombinant HBs (e.g., SEQ ID NO:1), amino acids 1-149 of HBc (e.g., SEQ ID NO:2), and an adjuvant comprising MPL and QS-21, and a liposome comprising dioleoylphosphatidylcholine (DOPC) and cholesterol. In certain embodiments, the recombinant protein HBs and HBc antigens are in the form of virus-like particles. In certain embodiments, the composition comprises a truncated recombinant HBc and full-length recombinant HBs in a ratio of 4:1 or greater, and an AS01 adjuvant. In certain embodiments, the composition comprises a truncated core antigen consisting of amino acids 1-149 of HBc (e.g., SEQ ID NO:2) and full-length recombinant HBs (e.g., SEQ ID NO:1) in a ratio of 4:1, and an AS01 adjuvant. B-4 Includes.
[0091] In another aspect, there is provided a use of an immunogenic composition in the manufacture of a medicament for treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs), a nucleic acid encoding hepatitis B core antigen (HBc), and a nucleic acid encoding human invariant chain (hIi) fused to HBc, and a method of treating chronic hepatitis B infection comprising administering the composition in a prime-boost regimen with at least one other immunogenic composition. In one embodiment, the composition comprises a ChAd vector selected from the group consisting of ChAd3, ChAd63, ChAd83, ChAd155, ChAd157, Pan 5, Pan 6, Pan 7 (also referred to as C7), and Pan 9, in particular ChAd63 or ChAd155. In certain embodiments, the ChAd vector comprises a vector insert encoding HBc and HBs separated by a spacer incorporating a sequence encoding the 2A cleavage region of foot and mouth disease virus. In certain embodiments, the composition comprises a polynucleotide vector insert encoding hIi, HBc, 2A, and HBs, e.g., a ChAd155 vector comprising an insert encoding a construct having a structure shown in Figure 22. In certain embodiments, the vector insert encodes HBc (e.g., SEQ ID NO: 11, or an amino acid sequence at least 98% identical thereto) and HBs (e.g., SEQ ID NO: 1, or an amino acid sequence at least 98% identical thereto), separated by a sequence encoding a spacer incorporating the 2A cleavage region of foot and mouth disease virus (e.g., SEQ ID NO: 3, or an amino acid sequence at least 98% identical thereto). In certain embodiments, HBc (e.g., SEQ ID NO:11, or an amino acid sequence at least 98% homologous thereto) is fused to a hIi (e.g., SEQ ID NO:7, or an amino acid sequence at least 98% homologous thereto, or SEQ ID NO:12, or an amino acid sequence at least 98% homologous thereto). For example, HBc (e.g., SEQ ID NO:11) is fused to a hIi (e.g., SEQ ID NO:7), or HBc (e.g., SEQ ID NO:11) is fused to a hIi (e.g., SEQ ID NO:12).In one embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 9. In an alternative embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO: 15. In one embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence set forth in SEQ ID NO: 10. In an alternative embodiment, the composition comprises a ChAd155 vector comprising a polynucleotide vector insert having a nucleotide sequence set forth in SEQ ID NO: 14.
[0092] In a further aspect, there is provided a use of an immunogenic composition in the manufacture of a medicament for treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs) and a nucleic acid encoding hepatitis B virus core antigen (HBc), and a method of treating chronic hepatitis B infection comprising administering the composition in a prime-boost regimen with at least one other immunogenic composition. In one embodiment, the composition comprises an MVA vector comprising vector inserts encoding HBc and HBs separated by a spacer incorporating a sequence encoding the 2A cleavage region of foot and mouth disease virus. In a particular embodiment, the composition comprises an MVA vector comprising polynucleotide vector inserts encoding HBc, 2A and HBs, e.g., an insert encoding a construct having a structure as shown in FIG. 21. In a particular embodiment, the vector insert encodes HBc (e.g., SEQ ID NO:11, or an amino acid sequence at least 98% homologous thereto) and HBs (e.g., SEQ ID NO:1, or an amino acid sequence at least 98% homologous thereto) separated by a sequence encoding a spacer (e.g., SEQ ID NO:3, or an amino acid sequence at least 98% homologous thereto) incorporating the 2A cleavage region of foot and mouth disease virus. In one embodiment, the composition comprises an MVA vector comprising a polynucleotide vector insert encoding the amino acid sequence of SEQ ID NO:5. In one embodiment, the composition comprises an MVA vector comprising a polynucleotide vector insert having the nucleotide sequence shown in SEQ ID NO:6.
[0093] In a further aspect, there is provided a use of an immunogenic composition in the manufacture of a medicament for treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising recombinant hepatitis B surface antigen (HBs), a C-terminal truncated recombinant hepatitis B core antigen (HBc), and an adjuvant comprising MPL and QS-21, and a method of treating chronic hepatitis B infection comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition. In one embodiment, the composition comprises a truncated recombinant HBc comprising the assembly domain of HBc, e.g., amino acids 1-149 of HBc. In one embodiment, the composition comprises full length recombinant HBs (e.g., SEQ ID NO: 1), amino acids 1-149 of HBc (e.g., SEQ ID NO: 2), and an adjuvant comprising MPL and QS-21 (e.g., an AS01 adjuvant, e ... B-4 Or AS01 E-4 In a specific embodiment, the recombinant protein HBs and HBc antigens are in the form of virus-like particles.
[0094] In one embodiment, there is provided the use of an immunogenic combination in the manufacture of a medicament for the treatment of chronic hepatitis B infection (CHB) in a human, the immunogenic combination comprising: i. a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); ii. a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and iii. Compositions Comprising Recombinant Hepatitis B Surface Antigen (HBs), Recombinant Hepatitis B Core Antigen (HBc) and an Adjuvant wherein a method for treating chronic hepatitis B infection comprises sequentially or simultaneously administering the compositions to a human.
[0095] In certain embodiments, the use of the immunogenic combination in the manufacture of a medicament for the treatment of CHB comprises: i. a composition comprising a replication-deficient ChAd vector comprising a polynucleotide encoding HBs, a nucleic acid encoding HBc, and a polynucleotide encoding hIi; ii. a composition comprising an MVA vector comprising a polynucleotide encoding HBs and a nucleic acid encoding HBc; and iii. Compositions Comprising Recombinant HBs, Truncated HBc, and an Adjuvant Comprising MPL and QS-21 The method for treating CHB comprises: a) administering composition i. to a human; b) administering composition ii. to a human; and c) administering composition iii. to a human. wherein the method steps are performed sequentially, with step a) preceding step b), which in turn precedes step c). In a further embodiment, step c is repeated, with the method steps being performed sequentially in the order a), b), c), c). In another embodiment, step c) is performed simultaneously with step a) and / or step b).
[0096] In a further aspect, the present invention provides a method for producing a method for treating a cancer cell comprising the steps of: a) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) Compositions comprising recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B core antigen (HBc) and an adjuvant together with instructions for administering the components sequentially or simultaneously for the treatment of CHB.
[0097] Administration In one embodiment of the disclosed method, the disclosed composition is administered via an intranasal, intramuscular, subcutaneous, intradermal, or topical route. Preferably, administration is via the intramuscular route.
[0098] Intranasal administration is the administration of the composition to the mucous membrane of the complete airway, including the lungs. More specifically, the composition is administered to the mucous membrane of the nose. In one embodiment, intranasal administration is achieved by spray or aerosol. Intramuscular administration refers to the injection of the composition into any muscle of an individual. Exemplary intramuscular injections are administered into the deltoid, vastus lateralis, or ventral and dorsoventral gluteal regions. Preferably, administration is performed into the deltoid muscle. Subcutaneous administration refers to the injection of the composition into the subcutaneous tissue. Intradermal administration refers to the injection of the composition into the dermis between layers of skin. Topical administration is the administration of the composition to any part of the skin or mucous membrane without penetrating the skin with a needle or equivalent device. The composition may be administered locally to the mucous membrane of the mouth, nose, genital area, and / or rectum. Topical administration includes administration means such as sublingual and / or buccal administration. Sublingual administration is the administration of the composition under the tongue (e.g., using an oral thin film (OTF)). Buccal administration is the administration of the vector through the buccal mucosa of the cheek.
[0099] The methods disclosed herein can take the form of a prime-boost immunization regimen. Thus, compositions for use in the method of treating CHB, which is a prime-boost immunization method, are disclosed herein. In many cases, a single administration of an immunogenic composition is not sufficient to generate the number of long-term immune cells required for effective protection or therapeutic treatment of a disease. As a result, repeated administration of a biological preparation specific to a particular pathogen or disease may be necessary to establish a sustained and protective immunity against said pathogen or disease, or to treat or functionally cure a given disease. An administration regimen that includes repeated administration of an immunogenic composition or vaccine against the same pathogen or disease is called a "prime-boost regimen." In one embodiment, a prime-boost regimen includes at least two administrations of an immunogenic composition against Hepatitis B. The first administration of an immunogenic composition is called "priming" and any subsequent administration of the same immunogenic composition, or an immunogenic composition against the same pathogen, is called "boosting." It should be understood that 2, 3, 4 or even 5 administrations to boost immune response are also contemplated. The period between prime and boost is 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks or 12 weeks, as the case may be. More specifically, it is 4 weeks or 8 weeks. When more than one boost is performed, the subsequent boost is administered 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks or 12 weeks, 6 months or 12 months after the preceding boost. For example, the interval between any two boosts may be 4 weeks or 8 weeks.
[0100] The compositions for use in the disclosed methods are administered in a treatment regimen that includes the administration of additional immunogenic components, each formulated in a different composition. The compositions are conveniently administered co-locationally, at or near the same site. For example, the components can be administered intramuscularly to the same side or limb ("co-lateral" administration) or to the opposite side or limb ("contra-lateral" administration). For example, in contralateral administration, a first composition may be administered to the left deltoid muscle and a second composition may be administered, either sequentially or simultaneously, to the right deltoid muscle. Alternatively, in ipsilateral administration, a first composition may be administered to the left deltoid muscle and a second composition may also be administered, either sequentially or simultaneously, to the left deltoid muscle.
[0101] General Manufacturing Process ●ChAd155-hIi-HBV: The DNA fragment inserted as a transgene into the recombinant replication-deficient simian (chimpanzee-derived) adenovirus group C vector ChAd155 is derived from two HBV protein antigens, the core nucleocapsid protein antigen HBc and the small surface antigen HBs, separated by the self-cleaving 2A region of the foot-and-mouth disease virus (FMDV) [Donnelly et al. 2001]. The 2A region of FMDV allows processing of the HBc-HBs fusion into separate protein antigens. In addition, the N-terminal part of the gene encoding the HBc protein is fused to a gene encoding the human major histocompatibility complex (MHC) class II-binding invariant chain p35 isoform (hIi). A schematic diagram of the hIi-HBV transgene sequence is provided in (Figure 22).
[0102] The 2A domain (18 amino acids) is supplemented with a 6 amino acid spacer at its N-terminus; this type of spacer has been reported to increase the efficiency of 2A-mediated cleavage. Protease cleavage via domain 2A occurs at the C-terminus of 2A, immediately prior to the last proline in the 2A amino acid sequence. The proline remains at the N-terminus of the HBs protein, while the 23 amino acids preceding the proline cleavage site remain with the hIi-HBc-2A polypeptide.
[0103] Expression of the transgene thereby results in the production of two separate polypeptides, following protease processing: hIi-HBc-spacer-2A and HBs. For simplicity, the hIi-HBc-spacer-2A polypeptide is referred to as the hIi-HBc protein. When expressed in cell culture, the hIi-HBc antigen is detected in the cell culture supernatant, while the HBs protein is detected in the intracellular fraction.
[0104] An expression cassette encoding an antigen protein (operably linked to regulatory elements to permit expression in a host cell) is assembled into a ChAd155 vector plasmid construct as previously described (see WO2016 / 198621, incorporated by reference for purposes of disclosing ChAd155 vector sequences and methods) to give ChAd155-hIi-HBV. The hIi-HBV transgene is under the transcriptional control of the human cytomegalovirus (hCMV) promoter and the bovine growth hormone polyadenylation signal (BGH pA). The expression cassette encodes HBs, HBc and hIi amino acid sequences, in which the hIi sequence is fused to the HBc N-terminus of HBc, and the HBs and HBc sequences are separated by a spacer incorporating the 2A cleavage region of foot and mouth disease virus for processing HBc and HBs into separate proteins.
[0105] To generate a recombinant ChAd155 adenovirus that is replication-deficient, the functions of the deleted gene regions required for adenovirus replication and infectivity must be provided to the recombinant virus by a helper virus or cell line, i.e., a complementing or packaging cell line. A particularly suitable complementing cell line is the Procell92 cell line. The Procell92 cell line is based on HEK 293 cells expressing the adenovirus E1 gene, transfected with the Tet repressor under the control of the human phosphoglycerate kinase-1 (PGK) promoter and the G418 resistance gene (Vitelli et al. PLOS One (2013) 8(e55435):1-9). Procell92.S is adapted to growth in suspension and is useful for the generation of adenovirus vectors expressing toxic proteins.
[0106] Production of ChAd155-hIi-HBV Drug Substance: The production of ChAd155-hIi-HBV viral particles (drug substance) was 5 × 10 5 The method involves culturing Procell-92.S cells at a cell density of 100 cells / ml. The cells are then infected with ChAd155-hIi-HBV master virus seed (MVS) using a multiplicity of infection of 200 vp / cell. The ChAd155-hIi-HBV virus harvest is purified by a multi-step process that includes cell lysis, lysate clarification, and concentration (filtration step), followed by anion exchange chromatography.
[0107] Vaccine Formulation and Filling The purified ChAd155-hIi-HBV bulk drug substance is then processed as follows: - Dilution of purified ChAd155-hIi-HBV drug substance in formulation buffer. - Sterile filtration. - Filling of final containers.
[0108] The ChAd155-hIi-HBV vaccine is a liquid formulation in a vial. The formulation buffer contains Tris (10 mM), L-histidine (10 mM), NaCl (75 mM), MgCl (1 mM) and EDTA (0.1 mM), with sucrose (5% w / v), polysorbate-80 (0.02% w / v) and ethanol (0.5% w / v), adjusted to pH 7.4 with HCl (water for injection to final volume).
[0109] ●MVA-HBV: MVA-HBV is a recombinant modified vaccinia virus Ankara (MVA) carrying two distinct proteins of HBV: core and S proteins (separated by the 2A peptide). The MVA-HBV construct was generated from the MVA-Red vector system [Di Lullo et al. 2010], derived from an MVA virus seed batch from the attenuated passage 571 (called MVA-571) described by Professor Anton Mayr [Mayr, A. et al. 1978].
[0110] The MVA-HBV transgene encodes the core nucleocapsid protein HBc and the small surface antigen HBs of HBV. The HBc-HBs sequences are separated by the self-cleaving 2A region of the foot and mouth disease virus, which allows for processing of the fusion protein into separate HBc and HBs antigens, as described above for the adenoviral vector. A schematic diagram of the transgene is provided in FIG.
[0111] Expression of the transgene results in the production of two separate polypeptides, after protease processing: HBc-spacer-2A and HBs. For simplicity, the HBc-spacer-2A polypeptide will be referred to as the HBc protein.
[0112] The expression cassette was subcloned into the MVA shuttle vector p94-elisaRen to generate the transfer vector p94-HBV, which contains the antigen expression cassette under the control of the vaccinia P7.5 early / late promoter, flanked by the FlankIII-2 and FlankIII-1 regions, allowing insertion into del III of MVA by homologous recombination.
[0113] The generation of recombinant viruses was based on two events of in vivo recombination in CEF cells.
[0114] Briefly, primary chicken embryo fibroblasts (CEF) were infected with MVA-Red and then transfected with p94-HBV carrying the antigen transgene (and the EGFP marker gene under the control of the synthetic promoter sP). The first recombination event occurs between homologous sequences (FlankIII-1 and FlankIII-2 regions) present in both the MVA-Red genome and the transfer vector p94-HBV, resulting in the replacement of the Hcred protein gene with the transgene / eGFP cassette. Infected cells containing MVA-Green intermediates are isolated by FACS sorting and used to infect fresh CEF. The intermediate recombinant MVA resulting from the first recombination carries both the transgene and the eGFP cassette, but is unstable due to the presence of the repeated Z region.
[0115] Thus, a spontaneous second recombination event involving the Z region occurs, removing the eGFP cassette. The resulting recombinant MVA is colorless and carries the transgene cassette.
[0116] Finally, markerless recombinant virus (MVA-HBV) infected cells were sorted by FACS, and MVA-HBV was cloned by terminal dilution and propagated in CEF by conventional methods.
[0117] Production of MVA-HBV drug substance MVA-HBV viral particles (drug substance) were 1×10 6 ~2×10 6 HBV is produced in primary cell cultures of chicken embryo fibroblasts (CEF) to a cell density of 100 cells / ml and then infected with MVA-HBV master virus seed (MVS) at a multiplicity of infection of 0.01-0.05 PFU / cell. MVA-HBV virus harvest is purified by a multi-step process based on centrifugation pelleting, resuspension, and differential gradient centrifugation steps.
[0118] Vaccine Formulation and Filling The purified MVA-HBV bulk drug substance is then processed as follows: - Dilution of purified MVA-HBV DS in formulation buffer. - Filling of final containers.
[0119] The MVA-HBV vaccine is a liquid formulation packaged in a vial. The formulation buffer contains tris(hydroxymethyl)aminomethane pH 7.7 (10 mM), NaCl (140 mM), and water for injection to final volume.
[0120] HBs-HBc recombinant protein mixture: HBc Drug Substance Production The HBc recombinant protein (drug substance) manufacturing process consists of inoculating pre-culture flasks with recombinant Escherichia coli (E. coli) working seed, followed by a fermentation process and a multi-step purification process that includes harvesting, extraction, clarification, and multiple chromatography and filtration steps.
[0121] Production of HBs drug substance The HBs recombinant protein (drug substance) manufacturing process consists of inoculating pre-culture flasks with recombinant S. cerevisiae working seed, followed by a fermentation process and a multi-step purification process that includes harvesting, extraction, clarification, and multiple chromatography and filtration steps.
[0122] Vaccine Formulation and Filling The purified HBs drug substance and HBc drug substance are diluted in a formulation buffer containing sucrose as a cryoprotectant and poloxamer as a surfactant, filled into 4 mL clear glass vials, and lyophilized. EXAMPLES
[0123] Preclinical development objectives: Strong and functional CD8, especially against HBcAg + and CD4 + T cell responses are associated with HBV clearance and resolution of infection [Boni, 2012; Li, 2011; Liang, 2011; Lau, 2002; Bertoletti, 2012]. Furthermore, anti-S antibodies may be key to prevent the spread of HBV to uninfected hepatocytes and control post-treatment relapse of HBV replication [Rehermann 2005; Neumann 2010]. The proposed vaccination regimen would involve the administration of strong CD8 + A heterologous prime-boost schedule using two viral vectored vaccines (ChAd155-hIi-HBV and MVA-HBV) encoding hepatitis B core (HBc) antigen and hepatitis B surface (HBs) antigen to induce T cell responses was shown to result in potent antigen-specific CD4 T cell responses in CHB patients. + AS01 for inducing T cell and antibody responses B-4 This vaccine-induced immune response should ultimately lead to a substantial reduction in HBsAg concentrations or HBsAg loss (i.e., HBsAg concentrations below detectable levels), which is considered a marker of complete and durable control of HBV infection.
[0124] The primary objectives of preclinical development were to: - Selection of vector constructs, inclusion of hIi, composition of protein formulations including adjuvant system selection, and immunization schedules, and evaluation of investigational vaccine components, e.g., ChAd155-hIi-HBV, MVA-HBV, and HBc-HBs / AS01B-4 To demonstrate the immunogenicity of in naive and HBV-tolerant mice. • To demonstrate the safety of the complete vaccine regimen in HBV-tolerant mice (non-GLP study) and in a repeat-dose GLP toxicity study conducted in NZW rabbits. • To document the biodistribution of vector in vaccinated animals (GLP study).
[0125] Preclinical strategies and rationale for the selection of animal models To guide the selection of vector constructs, protein formulations including adjuvant system selection, and immunization schedules, immunogenic packages were first generated in healthy mice.
[0126] To support the selection of vector constructs, protein formulations including adjuvant system selection, and immunization schedules, most of the preclinical experiments were performed in inbred CB6F1 (a hybrid of C57Bl / 6 and BALB / c mice) mice, a model previously used to evaluate T cell responses elicited by AS01-adjuvanted candidate vaccines and adenoviral vectors [Lorin, 2015].
[0127] Using HLA.A2 / DR1 mice (transgenic for human HLA-A2 and HLA-DR1 molecules), candidate vaccines were identified that express HBc-specific CD8 + The ability to induce T cell responses was evaluated (since no such responses were detected against this antigen in inbred CB6F1 mice), likely due to the presence of H2-K in the HBc sequence of the investigational vaccine. b This is due to the absence of the MHC-I restricted immunodominant epitope (MGLKFRQL). The HBc sequence of the investigational vaccine is based on the sequence of HBV genotype A / subtype adw, which differs by one amino acid, with an isoleucine (I) replacing a phenylalanine (F) in the epitope (MGLKIRQL) as reported by Riedl et al. [Riedl, 2014]. HBV-specific CD4 +T cells and antibodies were evaluated in the same HLA.A2 / DR1 mice.
[0128] Since HBV naturally infects only chimpanzees and humans, only limited animal models are available to evaluate the efficacy of therapeutic vaccines. Mouse models have been developed in which the entire HBV genome is expressed by integration of the viral genome in the host genome (HBV transgenic mice), or by infection with replicating HBV DNA, or by vectors expressing the HBV genome. Although these do not recapitulate chronic HBV pathogenesis, viral replication intermediates and proteins can be detected in the liver and immune tolerance is observed.
[0129] The AAV2 / 8-HBV transduced HLA.A2 / DR1 mouse model recapitulates the virological and immunological characteristics of chronic HBV infection. To demonstrate that the vaccine regimen can overcome tolerance to HBs and HBc antigens To evaluate the effect of liver-infiltrating HBc-specific CD8+ T cells, potentially targeting HBcAg-expressing hepatocytes, on liver histology (hematoxylin-eosin [H&E] staining) and ALT / AST levels. [Dion, 2013; Martin, 2015].
[0130] Finally, standard animal models for biodistribution (Sprague-Dawley rats) and toxicology studies (NZW rabbits) have been chosen to evaluate candidate vaccines because, although they are not models of infectious diseases, they are able to mount pharmacologically relevant immune responses against vector-expressed and recombinant proteins and are well-accepted species for vaccine toxicity testing. These species have also been shown to be effective in preventing and treating AS01 infections. B It has been used previously in toxicology testing programs for the adjuvants and immune enhancers MPL and QS-21.
[0131] Nonclinical Pharmacology Investigational vaccine components, e.g., ChAd155-hIi-HBV, MVA-HBV, and HBc-HBs / AS01, following intramuscular administration B-4 Several preclinical studies were performed to demonstrate the immunogenicity of the vaccine in naïve and HBV-tolerant animals. Antigen-specific immunogenicity profiles were first assessed using viral vector (ChAd155-hIi-HBV and MVA-HBV) and HBV recombinant protein adjuvanted investigational vaccines (HBc-HBs / AS01). B-4 The immunogenicity and safety profile of the complete vaccine regimen intended for first time in humans (FTiH) was evaluated in phase 2.
[0132] material Doses of AS01 adjuvant system used in non-clinical immunogenicity studies AS01 B-4 The adjuvant system is composed of the immune enhancers QS-21 (a triterpene glycoside purified from the bark of Quillaja saponaria) and MPL (3-D monophosphoryl lipid A), as well as liposomes and sorbitol as vehicles for these immune enhancers. B-4 A single human dose (0.5 mL) of contains 50 μg of QS-21 and 50 μg of MPL. 1 / 10 of the human dose, i.e., 50 μl, is the volume injected into mice (corresponding to 5 μg of QS-21 and MPL).
[0133] AS01 E-4 The adjuvant system is AS01 B-4 This corresponds to a 2-fold dilution of the dilution. 1 / 10 of the human dose, i.e. 50 μl, is the volume injected into the mice (corresponding to 2.5 μg of QS-21 and MPL).
[0134] Cellular immune response - Intracellular cytokine staining (ICS) Fresh pools of peripheral blood leukocytes (PBLs), splenocytes, or liver-infiltrating lymphocytes collected at various time points were stimulated ex vivo for 6 h with pools of 15-mers overlapping 11 amino acids covering the HBc or HBs sequence. HBc- and HBs-specific cellular responses were detected by CD4+ / -expressing IFN-γ and / or IL-2 and / or tumor necrosis factor (TNF)-α. + or CD8 + The results were assessed by ICS, which measures the amount of CD8 T cells. + T or CD4 + The minimum number of T cells included was >3000 events. Alternatively, IFN-γ-ELISpot was performed after restimulation of splenocytes with the same peptides as for ICS.
[0135] Humoral immune response - enzyme-linked immunosorbent assay (ELISA) HBc and HBs specific antibody responses were measured by ELISA on sera from immunized mice at various time points. Briefly, 96-well plates were coated with HBc or HBs antigen. Individual serum samples were then added in serial dilutions and incubated for 2 hours. Biotinylated anti-mouse F(ab)'2 fragments were then added and antigen-antibody complexes were revealed by incubation with streptavidin horseradish peroxidase complex and peroxidase substrate ortho-phenylenediamine dihydrochloride / H2O2. For each time point and each antigen (HBc, HBs), an analysis of variance (ANOVA) model was fitted to the log10 titers using a heteroscedastic model (identical variances between groups were not assumed), including group, study and interaction as fixed effects. This model was used to estimate the geometric means (and their 95% CI) and the geometric mean ratios and their 95% CI. As no predefined criteria were set, the analyses were descriptive and 95% CIs of the ratios between groups were calculated without adjustment for multiplicity.
[0136] ALT / AST measurement The levels of ALT and AST in mouse serum were quantified using the following commercially available kits: Alanine Aminotransferase Activity Assay Kit Sigma Aldrich Catalog #MAK052 Aspartate Aminotransferase Activity Assay Kit Sigma Aldrich Catalog #MAK055
[0137] Quantification of serum HBsAg Circulating HBs antigen in mouse serum was quantified using Monolisa Anti-HBs PLUS from BIO-RAD (catalog #72566) and an international standard (Abbott Diagnostics).
[0138] Histopathology analysis Livers (one lobe per liver) were harvested and preserved in 10% formaldehyde fixative. All samples for microscopic examination were trimmed according to RITA guidelines [Ruehl-Fehlert, 2003; Kittel 2004; Morawietz 2004], embedded in paraffin wax, sectioned to a thickness of approximately 4 microns, and stained with H&E. Grading of histological activity (necroinflammatory lesions) and fibrosis was performed according to the METAVIR scoring system [Bedossa, 1996; Mohamadnejad, 2010; Rammeh, 2014]. Grading of inflammatory cell foci was performed according to the Desmet score as described by Buchmann et al. [Buchmann, 2013].
[0139] The statistical analyses performed in each study are detailed in the sections relating to each individual study.
[0140] Example 1 - Evaluation of ChAd155-HBV (with and without hIi) prime and MVA-HBV boost in an HLA.A2 / DR1 transgenic mouse model the purpose The primary objective of this study was to demonstrate that priming with a single dose of ChAd155-HBV (with or without hIi) followed by a booster dose of MVA-HBV induced potent CD8 responses against HBc in HLA.A2 / DR1 mice transgenic for human MHC-I / II molecules. + The aim of this study was to determine whether ChAd155-HBV with and without hIi could induce HBc-specific CD8 T cell responses. Furthermore, a direct comparison was performed between ChAd155-HBV with and without hIi and demonstrated that HBc-specific CD8 T cell responses could be induced by hIi-specific antibodies, as previously reported for other antigens [Spencer, 2014; Capone, 2014]. + The potential of the hIi sequence to further increase T cell responses was investigated. + T cell responses and HBc and HBs-specific CD4 + T cell and antibody responses were also assessed.
[0141] research design HLA.A2 / DR1 mice (11 mice per group) were immunized with 10 8 Immunized with ChAd155-HBV (with or without hIi) in the vp and 10 days after immunization 7 Mice were sacrificed 14 days (14dpI) after the first immunization (prime) or 7 days (7dpII) after the second immunization (boost) to determine HBc- and HBs-specific humoral and cellular immune responses in serum and spleen, respectively.
[0142] [Table 1]
[0143] statistical analysis The ANOVA model included the two groups (with or without hIi) and the experiment (results of three experiments after prime and two experiments after boost) as fixed parameters, using a heteroscedastic model to estimate the log10 CD8 +The model was used to estimate the geometric means (and their 95% CI) and the geometric mean ratios and their 95% CI.
[0144] result HBc and HBs-specific T cell responses Both the ChAd155-HBV and ChAd155-hIi-HBV vectors express HBc-specific CD8 + The presence of hIi induced a higher CD8 T cell response to HBc antigen (Figure 1A). + MVA-HBV boosting of mice immunized with ChAd155-hIi-HBV tends to induce HBc-specific CD8 T cell responses. + It induced a 3-fold increase in T cell responses, whereas no increase was observed for the ChAd155-HBV group.
[0145] Both vectors express HBs-specific CD8 + T cell responses were induced, and the MVA-HBV booster effect was more pronounced in mice primed with the ChAd155-HBV construct (Figure 1B).
[0146] HBc and HBs specific CD4 + T cell responses were low (data not shown).
[0147] The results of this experiment were consistent with those of two other similar independent experiments (data not shown). Because of limitations related to animal availability, each independent study was not statistically powered to compare groups, but a meta-analysis of the three studies was performed to determine the relative HBc-specific CD8+ / -induced by ChAd155-HBV versus ChAd155-hIi-HBV after priming and MVA-HBV boost. + T cell responses were compared.
[0148] Statistical analysis showed that HBc-specific CD8+ cells were induced by the prime-boost regimen using the ChAd155-hIi-HBV construct after prime and MVA-HBV boost.+ It was shown that T cell responses were significantly higher than those elicited by a prime-boost regimen using ChAd155-HBV, supporting the use of a human invariant chain sequence fused to the HBc sequence. a. 14 days after Dose I, the geometric mean ratio (hIi / no hIi) was estimated to be 3.27 (95% CI: 1.57-6.79). b. Seven days after Dose II, the geometric mean ratio (hIi / no hIi) was estimated to be 6.25 (95% CI: 2.11 to 18.51).
[0149] HBc and HBs specific antibody responses Immunization with ChAd155-HBV induced HBc-specific antibodies, whereas immunization with ChAd155-hIi-HBV did not. After the MVA-HBV booster, anti-HBc antibody responses were comparable between groups primed with ChAd155-HBV or ChAd155-hIi-HBV (Figure 2). No HBs-specific antibody responses were detected (data not shown).
[0150] conclusion ChAd155-hIi-HBV had the highest CD8 immunization against HBc when compared with ChAd155-HBV. + It induced a T cell response that was further increased after an MVA-HBV boost.
[0151] Example 2 - HBc-HBs / AS01 in inbred mice (CB6F1) B-4 Immunogenicity research] the purpose The primary objective of this immunogenicity study was to determine whether HBc and HBs proteins were associated with AS01 B-4 The objective of this study was to determine whether HBc- and HBs-specific humoral and T cell responses could be induced when co-formulated into a HBV antibody solution.
[0152] research design Six to eight week old CB6F1 mice (30 mice per group) were cultured in 50 μl of AS01 B-4Mice were immunized three times intramuscularly with HBc, HBs, or HBc-HBs (listed in Table 2 below) formulated in immunized mice on days 0, 14, and 28. HBc- and HBs-specific T cell responses were measured in fresh PBL 7 days after the second and third doses, and anti-HBs and anti-HBc antibody responses were measured 14 days after the second and third doses.
[0153] [Table 2]
[0154] statistical analysis Statistical analysis was performed using ANOVA on log10 values with one factor (group) using a heteroscedastic model, i.e., identical variance was not assumed for different levels of the factor. The analysis included time points (after the second and third immunizations), T cell responses (CD4 + and CD8 + The mean ratios were calculated by 95% confidence interval (CI) and 95% confidence interval (CI) for each group. ...
[0155] result HBc and HBs-specific T cell responses HBc / AS01 B-4 , HBs / AS01 B-4 or HBc-HBs / AS01 B-4 Immunization of mice with IgG4 induced strong CD4 expression against both antigens. + induced a T cell response (Figure 3). + The magnitude of the T cell response was HBc-HBs / AS01 B-4 Regarding preparations, HBc / AS01 B-4 The HBc-specific CD4 +The levels of T cells were far greater than those in the control group and appeared to remain robust. + No such interference was observed on the level of T cell responses.
[0156] HBs / AS01 B-4 or HBc-HBs / AS01 B-4 The formulation contains a potent HBs-specific CD8 + As reported by others [Riedl, 2014], the HBc sequence of our vaccine candidate contains the H2-K b None of the vaccine candidates elicited detectable HBc-specific CD8+ cells, as expected in this mouse model, due to the absence of the MHC-I restricted immunodominant epitope -MGLKFRQL-. + It did not induce a T cell response (data not shown).
[0157] HBc and HBs specific antibody responses High levels of anti-HBc and / or anti-HBs antibodies were induced by each of the three formulations (see Figure 5). B-4 In the preparation, HBc / AS01 B-4 A significantly lower level of anti-HBc antibody response was observed in the HBc-HBs / AS01 group compared with the HBc-HBs / AS01 group (2.35-fold, P < 0.0001). B-4 The presence of HBc in the combination did not negatively affect the anti-HBs antibody response (Figure 5).
[0158] conclusion All preparations (HBs / AS01 B-4 , HBc / AS01 B-4 and HBc-HBs / AS01 B-4 ) was immunogenic and induced both cellular and humoral responses against both antigens (HBc-specific CD8 + (except for T cell responses) (as expected in this model). HBc-HBs / AS01 B-4 The anti-HBc response induced by the formulation was HBc / AS01 B-4This interference was further evaluated; see Example 7, in which a 4:1 ratio of HBc to HBs suppressed the anti-HBc immune response (antibodies and specific CD4+) without affecting the anti-HBs antibody response. + This preparation, HBc-HBs 4-1 / AS01, was able to restore the HBs T cells. B-4 was selected for subsequent non-clinical immunogenicity studies with adjuvanted protein formulations.
[0159] Example 3 - Comparative adjuvant experiment in inbred mice (CB6F1) the purpose The main purpose of this study was to compare the effects of various adjuvants (Alum, AS01 B-4 Or AS01 E-4 HBcAg and HBsAg in a 4:1 ratio formulated with or without adjuvant, providing potent CD4 binding to both antigens. + The ability to induce T cell and humoral responses was compared.
[0160] research design CB6F1 mice aged 6 to 8 weeks (35 mice for groups 1 to 4 and 25 mice for group 5) were cultured in a 10-mL broth culture medium containing Alum, AS01, 100 mL of broth, and 100 mL of broth. B-4 Or AS01 E-4 The mice were immunized three times intramuscularly on days 0, 14 and 28 with HBc-HBs antigen (4 μg-1 μg) formulated with AS01 (listed in Table 3 below). E-4 The adjuvant system is AS01 B-4 Contains half the amount of immune enhancers QS-21 and MPL compared to HBs-1.7. HBc- and HBs-specific T cell responses were measured in fresh PBLs 7 days after the second and third doses after 6 h of ex vivo restimulation with pools of peptides, and anti-HBs and anti-HBc antibody responses were measured by ELISA 14 days after the second and third doses.
[0161] [Table 3]
[0162] statistical analysis For statistical analysis, ANOVA models were fitted to log2 T cell frequencies and log10 antibody titers using a heteroscedastic model, including group as a fixed effect (identical variance between groups was not assumed, and the NaCl group was excluded from the analysis). Using this model, geometric means (and their 95% CI) and geometric mean ratios (ASO1 vs. the three other groups) were calculated. B ) and their 95% CIs were estimated. Dunnett's adjustments were performed for HBc and HBs-specific CD4 + This was applied to T cell frequencies (primary endpoint) and anti-HBs antibody titers (secondary endpoint) measured 14 days after the third dose. For other responses / time points, the analysis was descriptive and no adjustments were applied.
[0163] result HBc and HBs-specific T cell responses The AS01-adjuvanted formulation induced significantly higher HBc-specific CD4 expression compared with the alum-adjuvanted and non-adjuvanted formulations. + induced a T cell response (Figure 6B). B-4 Formulation and AS01 E-4 No statistically significant differences were observed between the formulations. As previously observed in CB6F1 mice, HBc-specific CD8 + T cell responses were undetectable whatever the formulation tested (data not shown).
[0164] The AS01-adjuvanted formulation showed a significant increase in HBs-specific CD4 expression compared with alum-adjuvanted and non-adjuvanted formulations. + (Figure 6A) and CD8 + (Figure 6C) T cell responses were significantly higher. B-4 Formulation and AS01 E-4 No statistically significant differences were observed between the formulations.
[0165] HBc and HBs specific antibody responses The AS01-adjuvanted formulation induced significantly higher anti-HBc and anti-HBs total IgG responses compared to the alum-adjuvanted and non-adjuvanted formulations (Figure 7). B-4 and AS01 E-4 The total IgG antibody responses elicited by the adjuvanted formulations were not statistically different.
[0166] conclusion Overall, the AS01 adjuvant system (AS01 E-4 Or AS01 B-4 ) induced the highest humoral and cellular responses against HBc and HBs in CB6F1 mice compared with alum-based or non-adjuvanted formulations.
[0167] Example 4 - ChAd155-hIi-HBV / MVA-HBV / HBs-HBc / AS01 in HLA.A2 / DR1 transgenic mice B-4 Immunogenicity evaluation of vaccine regimens] the purpose The objective of this study was to evaluate the efficacy and safety of ChAd155-hIi-HBV / MVA-HBV viral vector prime / boost followed by or co-administered with two doses of HBc-HBs 4-1 / AS01 B-4 The objective of this study was to evaluate the immunogenicity of different protein-based vaccine regimens.
[0168] research design Group 1 mice (N=16) were immunized with ChAd155-hIi-HBV on day 0, followed by MVA-HBV 28 days later. Two doses of HBc-HBs 4-1 μg / AS01 B-4 Mice in the second group (N=16) were injected with ChAd155-hIi-HBV and HBc-HBs 4-1 / AS01 on day 0 at 14-day intervals after this prime / boost viral vector regimen (Table 4). B-4 immunization with HBc-HBs 4-1 / AS01 28 days later. B MVA-HBV and HBc-HBs 4-1 / AS01 were co-administered with HBV and boosted with MVA-HBV.B Two subsequent co-immunizations of HBc and HBs were performed 14 days apart (Table 4). A third group of mice (N=8) was injected with NaCl as a negative control. Mice were sacrificed 7 days after the second and fourth immunizations (7dpII, 7dpIV, respectively) to determine HBc- and HBs-specific humoral (serum) and cellular immune responses (in splenocytes and liver-infiltrating lymphocytes).
[0169] This study was descriptive and no statistical sample size justification and analysis was performed.
[0170] [Table 4]
[0171] result HBc and HBs specific CD8 + T cell response (splenocytes) HBc-HBs 4-1 / AS01 B-4 Co-administration of ChAd155-hIi-HBV vector (as prime) and MVA-HBV vector (as boost) (group 2) significantly increased HBc-specific CD8 expression at 7 dpII when compared with injection of ChAd155-hIi-HBV / MVA-HBV alone (group 1). + The antibody induced a four-fold increase in the CD8 T cell response against HBs (Figure 8). + T cell responses were induced in both groups (Figure 8).
[0172] At 7dpIV, HBc-specific CD8 + T cell responses are HBc-HBs / AS01 B-4 There was a clear boost after subsequent administration of HBs-specific CD8 + T cell responses were not boosted (group 1). MVA-HBV / HBc-HBs 4-1 / AS01 B-4 When coadministered with two additional doses of + No further expansion of T cells was observed (group 2).
[0173] HBc and HBs specific CD4 + T cell response (splenocytes) Low levels of HBc and HBs-specific CD4 + T cells were detected after prime-boost ChAd155-hIi-HBV / MVA-HBV immunization (median 0.17% and 0.11%, respectively) (group 1), whereas HBc-HBs 4-1 / AS01 B-4 When was co-administered with prime-boost ChAd155-hIi-HBV / MVA-HBV, a strong response to both antigens was observed at 7dpII (group 2) (Figure 9).
[0174] HBc-HBs 4-1 / AS01 after ChAd155-hIi-HBV / MVA-HBV prime-boost B-4 Subsequent administration of HBc and HBs-specific CD4 + The HBc-HBs / AS01 antibody significantly enhanced T cell responses (median 1.64% and 2.32%, respectively). B-4 Mice already vaccinated with prime-boost ChAd155-hIi-HBV / MVA-HBV co-administered with two additional doses of MVA-HBV and HBc-HBs / AS01 B-4 When co-administered with HBs-specific CD4 + A robust increase in T cells was observed (group 2). + T cells remained at the same levels 7 days post II (7dpost II) in that same group.
[0175] HBc- and HBs-specific T-cell responses measured in liver-infiltrating lymphocytes. Seven days after the last immunization, the presence of vaccine-induced T cell responses in the liver was investigated by ICS. To ensure a sufficient number of liver-infiltrating lymphocytes to perform in vitro restimulation and ICS, a pool of cells collected after perfusion of three or four livers was constituted for each data point. Due to the small number of data points, no statistical analysis was performed and the results are descriptive.
[0176] Both vaccine regimens resulted in detectable HBc- and HBs-specific CD4 in the livers of vaccinated mice. + T cells (Figure 10). + T cell responses were measured in the livers of animals vaccinated with both vaccine regimens, whereas much lower frequencies of HBs-specific CD8 + T cells were measured.
[0177] HBc and HBs specific antibody responses ChAd155-hIi-HBV / MVA-HBV, HBc-HBs 4-1 / AS01 B-4 Co-administration with MVA-HBV+HBc-HBs / AS01 (Group 2) induced the highest amount of anti-HBc antibodies at 7 dpII (Figure 11). B-4 Subsequent injection of HBs-HBs / AS01 did not further increase the level of anti-HBc antibody responses (7 dpIV). B-4 A clear increase in anti-HBc specific antibody responses was observed 7 dpIV after injection of HBc-HBs / AS01 (group 1). Since no anti-HBs antibody responses were detected in animals after immunization with ChAd155-hIi-HBV / MVA-HBV, the HBc-HBs / AS01 antibody response was not detected in animals after immunization with ChAd155-hIi-HBV / MVA-HBV. B-4 The presence of the components appeared to be important in the schedule to induce strong anti-HBs antibodies (Figure 11). The greatest magnitude of response was observed in the co-administration group (Group 2) after the last immunization.
[0178] conclusion In HLA.A2 / DR1 transgenic mice, ChAd155-hIi-HBV / MVA-HBV induced low but detectable HBc-specific CD4 + It induces a T cell response, which is a HBc-HBs 4-1 / AS01 B-4 The initial prime-boost immunization with ChAd155-hIi-HBV / MVA-HBV induced potent HBc- and HBs-specific CD8 +T cell responses were induced, and HBc-specific responses were induced by sequentially administered HBc-HBs / AS01. B-4 It increased even more after the boost.
[0179] Interestingly, ChAd155-hIi-HBV / MVA-HBV inhibited HBc-HBs 4-1 / AS01 B-4 When coadministered with 、 High levels of HBc- and HBs-specific CD4 after only two immunizations + and CD8 + T cells and antibodies were induced. MVA-HBV+HBc-HBs / AS01 B-4 Further immunization with did not further increase the level of these responses.
[0180] In addition, vaccine-induced HBc and HBs-specific CD4 + and CD8 + T cells were also detected in the livers of animals vaccinated with both vaccine regimens.
[0181] Example 5 - Evaluation of T and B cell tolerance to the "invariant chain" sequence Ii encoded by the ChAd155 vector: Use of a ChAd155 construct encoding the murine Ii sequence (mIi) in CB6F1 mice. the purpose To investigate T and B cell tolerance to the "invariant chain" sequence Ii in an allogeneic model using a ChAd155 construct encoding the murine Ii sequence (mIi): ChAd155-mIi-HBV, immunogenicity studies were performed in CB6F1 mice.
[0182] research design Induction of autologous mIi-specific immune responses was performed using high doses (10 9 vp) by IFN-γ ELISpot (in splenocytes) and ELISA (in serum) after two intramuscular immunizations (days 0 and 14) with the ChAd155-mIi-HBV vector.
[0183] [Table 5]
[0184] method For T cell responses, 15-mer peptides encompassing the mouse Ii sequence and prepared in pools, overlapping by 11 amino acids, were used as antigens in IFN-γ-ELISpot assays. For antibody responses, commercially available mouse Ii recombinant protein and a monoclonal antibody specific for mouse Ii were used to coat ELISA plates and as positive controls, respectively. As a positive control for "vaccination", HBc- and HBs-specific T cell responses were monitored in IFN-γ-ELISpot assays.
[0185] result Strong HBc-specific and low but detectable HBs-specific T cell responses were measured after the first and second immunizations with ChAd155-mIi-HBV. Of note, the HBc Kb-restricted dominant class I epitope (MGLKFRQL) was added to this construct, which enhanced the upregulation of HBc-specific CD8 T cells in this mouse strain. + To allow monitoring of T cell responses, splenocytes were restimulated with this specific sequence in an ELISpot assay. Two weeks after the first or second immunization, no anti-mIi antibodies (Figure 13) or mIi-specific T cells (Figure 12) were detected in any of the animals, suggesting that immune tolerance to the mIi sequence was maintained.
[0186] Example 6 - ChAd155-hIi-HBV / MVA-HBV / HBc-HBs / AS01 in AAV2 / 8-HBV-transduced HLA.A2 / DR1 mice B-4 Immunogenicity and safety evaluation of vaccine regimens. the purpose The AAV2 / 8-HBV transduced HLA.A2 / DR1 mouse model recapitulates the virological and immunological characteristics of chronic HBV infection. In this model, mouse livers are transduced with an adeno-associated virus serotype 2 / 8 (AAV2 / 8) vector carrying a replication-competent HBV DNA genome.
[0187] 5 × 10 of AAV2 / 8-HBV vector 10 A single tail vein injection of vg (viral genome) results in HBV replication and gene expression in the liver of AAV2 / 8-HBV transduced mice [Dion; 2013]. HBV DNA replication intermediates, HBV RNA transcripts, and HBc antigen are detectable in the liver up to one year after injection, without associated significant liver inflammation. HBs and HBe antigens, as well as HBV DNA, can be detected in serum up to one year. Furthermore, the establishment of immune tolerance to HBV antigens is observed in this surrogate model of chronic HBV infection.
[0188] The objectives of this study, carried out in AAV2 / 8-HBV transduced HLA.A2 / DR1 mice, were to: To demonstrate that the vaccine regimen can overcome tolerance to HBs and HBc antigens - Liver-infiltrating HBc-specific CD8, potentially targeting hepatocytes expressing HBcAg, on liver histology (H&E staining) and AST and ALT levels (as surrogate parameters for liver function) + To assess the effect of T cells It was.
[0189] research design Alone or HBc-HBs 4-1 / AS01 B-4 ChAd155-hIi-HBV and MVA-HBV (both encoding HBV core [HBc] and surface [HBs] antigens) in combination with HBc-HBs 4-1 / AS01, followed by two booster doses of HBc-HBs 4-1 / AS01. B-4 Two different vaccine regimens, based on sequential immunization with HBV (alone or in combination with MVA-HBV), were tested (Table 6).
[0190] HLA.A2 / DR1 mice in groups 1, 2 and 3 were treated with 5 × 10 10 vg of AAV2 / 8-HBV vector (administered intravenously), while group 4 served as a positive control for immunogenicity (no establishment of tolerance prior to vaccination).
[0191] Group 1 animals (N=21) were immunized with ChAd155-hIi-HBV on day 31 followed by MVA-HBV on day 58. Two doses of HBc-HBs 4-1 μg / AS01 B-4 were injected on days 72 and 86 after this prime / boost viral vector regimen (Table 6).
[0192] Group 2 animals (N=21) were immunized with ChAd155-hIi-HBV on day 31 and HBc-HBs 4-1 / AS01 B-4 on day 58, followed by HBc-HBs 4-1 / AS01 B MVA-HBV and HBc-HBs 4-1 / AS01 were co-administered with HBV and boosted with MVA-HBV. B Two subsequent co-immunizations of were performed on days 72 and 86 (Table 6).
[0193] Group 3 animals (N=21) were injected with NaCl on days 31, 58, 72 and 86 as a negative control.
[0194] Group 4 animals (N=8) received the same vaccine regimen as Group 2 (except they were not transduced with AAV2 / 8-HBV).
[0195] All vaccines were administered intramuscularly.
[0196] Circulating HBs antigen levels were measured in serum on days 23, 65 and 93 (groups 1, 2 and 3).
[0197] HBs and HBc specific antibody responses were measured in the serum of all animals by ELISA on days 23 (after AAV2 / 8-HBV transduction), 65 (7 days after the second immunization) and 93 (7 days after the fourth immunization). + and CD8 + T cell responses were evaluated on days 65 (9 animals / group) and 93 (12 animals / group) in splenocytes and liver-infiltrating lymphocytes after ex vivo restimulation and ICS (groups 1, 2 and 3). These immunogenicity readouts were performed only on day 93 for group 4 animals (8 animals).
[0198] Regarding liver-related safety parameters, AST and ALT levels were measured in serum on days 38, 65 and 93, and microscopic examination of H&E stained liver sections was performed on days 65 and 93 to detect potential vaccine-related histopathological changes or inflammation (groups 1, 2 and 3).
[0199] [Table 6]
[0200] statistical analysis AST and ALT levels An ANOVA model for repeated measures including sex, day, group, and three 2x2 interactions was fitted to the log10 transformed enzyme activity values using an unstructured covariance structure. Model assumptions were tested. Interactions that were not significant at the 5% level were removed from the model. For both enzymes, the final model included sex, day, group, and the interaction between group and day. The geometric mean of enzyme activity for each group at each time point was derived from this model. Group comparisons of interest are reported by geometric mean ratios (GMRs), which were also derived from this model. All these statistics are presented with two-sided 95% confidence intervals. Multiplicity was not considered when calculating these GMRs.
[0201] All analyses were performed using SAS 9.2.
[0202] Humoral response Descriptive statistics were performed to calculate the number of responders. Cut-offs for responsiveness of anti-HBc or anti-HBs antibody responses were defined based on the geometric mean titers calculated in group 3 (AAV2 / 8-HBV transduced but unvaccinated).
[0203] Cellular Response HBc, HBs-specific CD4 + or CD8 + Descriptive analysis was performed to define the number of responders for any of the T cells. The cutoff for responsiveness was defined as the 95th percentile of measurements made in group 3 (AAV2 / 8-HBV transduced but unvaccinated).
[0204] result HBc-specific CD8 + and CD4 + T cells In AAV2 / 8-HBV-transduced HLA-A2 / DR1 mice, HBc-specific CD8 + or CD4 + Background levels of T cells were very low to undetectable without immunization at all time points tested (Group 3).
[0205] Alone (group 1) or HBc-HBs 4-1 / AS01 B-4 Immunization with ChAd155-hIi-HBV and MVA-HBV vectors in combination with (group 2) increased HBc-specific CD8 + T cell induction (6 / 7 and 9 / 9 responders, respectively, 7 days after II), demonstrating the escape of tolerance to HBc antigen (FIG. 14A). HBc-HBs 4-1 / AS01 alone or in combination with MVA-HBV B-4 Two additional doses of + It only modestly increased T cell responses, reaching a median frequency of 1% in group 1 and 1.45% in group 2. HBc-specific CD8 T cells induced by the same vaccine regimen as in group 2. +The frequency of HBc-specific CD8 T cells was higher in non-transduced HLA.A2 / DR1 mice in group 4 (8 / 8 responders, frequency was approximately 4-fold higher 7 days after IV), as expected due to immune tolerance to the HBc antigen. + T cells were also detected in the livers of vaccinated mice with the same profile as in the spleen (FIG. 14B).
[0206] Both vaccine regimens induced very low to undetectable HBc-specific CD4+ in AAV2 / 8-HBV-transduced HLA-A2 / DR1 mice. + T cells against the HBc antigen (groups 1 and 2), whereas a robust response was measured in non-transduced mice (group 4), indicating that the vaccine regimen was able to induce CD4 T cells against the HBc antigen under these experimental conditions. + These results suggest that T cell tolerance was not overcome (Fig. 15A, B).
[0207] HBs-specific CD8 + and CD4 + T cells Alone (group 1) or HBc-HBs 4-1 / AS01 B-4 Immunization with ChAd155-hIi-HBV and MVA-HBV vectors in combination with AAV2 / 8-HBV (group 2) increased HBs-specific CD8 + T cells were induced and two additional doses of HBc-HBs 4-1 / AS01 alone or in combination with MVA-HBV were administered. B-4 There was no further increase in intensity thereafter (Figure 16A). At the end of the vaccination schedule (7 days after the fourth dose), HBs-specific CD8 + The frequency of T cells was close to that detected in group 4 (non-transduced HLA.A2 / DR1 mice, median 7 days post-IV = 0.62%, 5 / 8 responders), suggesting overcoming T cell tolerance to HBsAg. + T cells were detected in the livers of animals in groups 1, 2 and 4 in most of the vaccinated animals (FIG. 16B).
[0208] HBs-specific CD4 + T cells were administered HBc-HBs 4-1 / AS01 alone or in combination with vector starting 7 days after the second vaccination in group 2 and starting 7 days after the fourth vaccination in group 1. B-4 The vaccine schedule used in animals in group 2 significantly increased HBs-specific CD4+ expression compared to the vaccine schedule used in animals in group 1 (median 7 days post-IV = 1.34%, 11 / 12 responders). + Approximately three times higher frequencies of T cells were induced (median 7 days post-IV = 3.7%, 11 / 11 responders), reaching similar levels as in group 4 (non-transduced HLA.A2 / DR1 mice, median 7 days post-IV = 3%, 8 / 8 responders), suggesting complete overcoming of T cell tolerance to HBsAg. + Similar to the T cell response, HBs-specific CD4 + T cells were detected in the liver of animals in groups 1, 2 and 4 in all vaccinated animals (Figure 17B).
[0209] HBs and HBc specific antibody responses 23 days after injection of the AAV2 / 8-HBV vector, anti-HBs antibody responses were not detected in HLA.A2 / DR1 mice, suggesting strong humoral tolerance to HBs antigen. Immunization with ChAd155-hIi-HBV and MVA-HBV vectors alone (group 1) did not destroy this tolerance, whereas HBc-HBs 4-1 / AS01 B-4 Immunization with the vector in combination with HBc-HBs 4-1 / AS01 resulted in the induction of anti-HBs antibody responses in 15 of 21 animals at day 65 (group 2) (Figure 18A). B-4 Further administration of 4-1 / AS01 induced detectable anti-HBs antibodies (geometric mean titer (GMT) of 116.8 at day 93 and 8 / 12 responders) and reduced HBc-HBs in group 2. B-4Two additional doses of MVA-HBV in combination with HBs further increased the strength of the anti-HBs antibody response in 11 / 11 responders to a GMT of 775 (although it remained approximately 5-fold lower than in non-AAV2 / 8-HBV-transduced animals in group 4 (GMT=3933) at day 93).
[0210] Similarly, HBc-HBs 4-1 / AS01 B-4 Anti-HBc antibody responses were induced only when the components were present in the vaccine regimen, with 3-fold higher levels measured at day 93 in animals from group 2 (GMT=1335.5; 11 / 11 responders) compared to group 1 (GMT=442.8; 12 / 12 responders) (FIG. 18B). Anti-HBc antibody titers induced in non-transduced mice (group 4) with the same vaccine regimen as in group 2 were higher (approximately 27-fold, GMT=35782).
[0211] These results indicate that the presence of adjuvanted protein components in the vaccine regimen is important in breaking humoral tolerance to both HBc antigen and HBs antigen. B-4 The vaccine regimen used in group 2, including four doses of HBV, induced the highest anti-HBc and anti-HBs antibody responses (although remaining lower than in non-AAV2 / 8-HBV transduced mice (group 4)).
[0212] AST / ALT levels As liver-related inflammation parameters, serum activity of AST and ALT was measured (all groups) on day 38 (7 days after the first vaccination), day 65 (7 days after the second vaccination), and / or day 93 (7 days after the fourth immunization). Overall, AST and ALT levels were stable in AAV2 / 8-HBV-transduced HLA.A2 / DR1 mice during the course of the vaccine regimen (groups 1 and 2) and were similar to those measured in unvaccinated mice (group 3) (Figure 19). AST levels were found to be statistically significantly higher in animals of the vaccine groups (groups 1 and 2) compared to control group 3 at day 65. However, AST levels were surprisingly low at day 65 in animals of group 3 compared to the rest of the kinetics, suggesting that these differences were due to a particularly unexpectedly low value obtained in control group 3 at this time point, rather than an increase in AST levels in the vaccine groups (groups 1 and 2) (Figure 19A).
[0213] Although slightly lower ALT levels were measured at day 38 in Group 1 animals compared to Group 3 control animals, this difference was not considered clinically relevant (FIG. 19B).
[0214] Liver microscopy Microscopic examination of H&E stained liver sections was performed on days 65 and 93 to detect potential vaccine-related histopathological changes or inflammation (Groups 1, 2 and 3) (Table 7).
[0215] In AAV2 / 8-HBV transduced HLA-A2 / DR mice, on day 65 (HBc-HBs 4-1 / AS01 B-4 There were no microscopic findings related to the laboratory parameters on either day 1 (7 days after the second injection of the viral vectored vaccine MVA-HBV with or without 4-1 / AS01) or day 93 (7 days after the last injection), i.e., vaccine components ChAd155-hIi-HBV, MVA-HBV and HBc-HBs 4-1 / AS01. B-4 There were no histopathological changes that could be related to the use of
[0216] Furthermore, with the exception of control animal 3.13 (which showed focal grade 1 piecemeal necrosis), none of the animals showed morphological signs of chronic hepatitis.
[0217] Other microscopic findings observed in treated animals were considered incidental changes as they also occurred in controls, were small in incidence / magnitude, and / or were common background findings in mice of similar age [McInnes, 2012].
[0218] [Table 7]
[0219] HBs antigen levels in serum of AAV2 / 8-HBV-injected mice As previously reported by Dion et al. [Dion, 2013], 23 days after injection with AAV2 / 8-HBV vectors, HBsAg levels were higher in males compared to females. These levels remained stable in all groups without detectable effects of the vaccination regimen (Figure 20). However, AAV2 / 8-HBV-injected mice are not an animal model for studying vaccine efficacy against HBsAg.
[0220] conclusion In a surrogate model of chronic HBV infection in which immune tolerance to HBc and HBs antigens is established, i.e., AAV2 / 8-HBV-transduced HLA-A2 / DR1 mice, both tested vaccine regimens induced HBc- and HBs-specific IgG and CD8 antigens, although at lower levels than in non-transduced mice, as expected for strong immune tolerance. + T cell responses and HBs-specific CD4 + The ChAd155-hIi-HBV / MVA-HBV vector circumvented tolerance by inducing T cell responses. B-4 When coadministered with 、The strength of vaccine-induced antibody and T cell responses was higher than with a vaccine regimen in which vector and adjuvanted protein were administered sequentially. Furthermore, vaccine-associated liver inflammation was evaluated by measuring serum activity of AST and ALT and performing liver histopathological evaluation, but no increase in liver enzymes was detected in the vaccine group when compared with the non-vaccinated ones, and none of the microscopic findings could be related to the vaccine treatment. Taken together, these results indicate that the tested vaccine candidate was able to induce HBs- and HBc-specific antibodies and CD8 expression without the detection of relevant signs of liver changes under these experimental conditions. + T cell responses and HBs-specific CD4 + 4 shows that T cell responses were successfully restored.
[0221] Summary of Nonclinical Immunology Data for Examples 1-6 AS01 B-4 Studies in CB6F1 mice vaccinated with vaccine protein (HBc-HBs) formulated in an adjuvant system demonstrated that HBc-induced antibodies and CD4 + This suggests a negative interference of HBsAg on T cell responses. Nevertheless, HBc-HBs / AS01 B-4 The combination vaccine showed robust specific CD4 responses to both vaccine antigens. + It was possible to mount a T cell and antibody response.
[0222] - When compared with alum-based or non-adjuvanted formulations, the AS01 family-based formulations demonstrated significantly higher CD4 activation for both HBcAg and HBsAg. + Induced T cell and antibody responses.
[0223] Administration of ChAd155-hIi-HBV in HLA.A2 / DR1 transgenic mice induced potent CD8 expression against HBc antigen. + Induce T cell responses and, to a lesser extent, CD8 +The response to HBcAg was clearly enhanced by the presence of the hIi in the construct. Subsequent administration of MVA-HBV induced CD8 T cell responses to HBcAg. + Further increased T cell responses: after MVA boost, mice primed with ChAd155-hIi-HBV showed increased HBc-specific CD8 + A higher frequency of T cells was observed, whereas HBs-specific CD8 + The T cell response was not further enhanced.
[0224] When administered to HLA.A2 / DR1 transgenic mice, the complete vaccination regimen (i.e., sequential or simultaneous administration of viral vector and adjuvanted protein) induced robust CD4 expression against both vaccine antigens. + T cells, CD8 + In addition, the vaccine induced HBs- and HBc-specific CD4 + and CD8 + T cells were detected in the livers of animals vaccinated with both vaccine regimens.
[0225] Immunogenicity studies were performed in CB6F1 to investigate T and B cell tolerance to the "invariant chain" sequence (Ii) in an allogeneic model using the ChAd155 construct encoding the murine Ii sequence (mIi): ChAd155-mIi-HBV. The induction of autologous mIi-specific immune responses was evaluated using a high dose (10 9 vp) with the ChAd155-mIi-HBV vector (days 0 and 14). Two weeks after the first or second immunization, no anti-mIi antibodies or mIi-specific T cells were detected in any of the animals, suggesting that immune tolerance to the mIi sequence was maintained.
[0226] In a preclinical HBV persistent mouse model (AAV2 / 8-HBV transduced HLA.A2 / DR1 mice) in which immune tolerance to HBV antigens is observed, a vaccine regimen was able to break tolerance and increase HBc- and HBs-specific CD8 + T cells, HBs-specific CD4 + T cell and antibody responses against both HBs and HBc antigens were induced (HBc-specific CD4 + (although no T cell responses were observed). However (and as expected), the level of vaccine-induced responses in AAV-transduced mice was lower than that detected in naive HLA.A2 / DR1 mice. Furthermore, vaccine-associated liver inflammation was assessed by measuring serum activity of aspartate aminotransferase (AST) and ALT and performing liver histopathological evaluation, but no increase in liver enzymes was detected in the vaccine group when compared to the non-vaccinated group, and none of the microscopic findings could be related to the vaccine treatment. Taken together, these results indicate that the tested vaccine candidate was able to elicit, under these experimental conditions, HBs- and HBc-specific antibodies and CD8 expression without the detection of relevant signs of liver alterations. + T cell responses and HBs-specific CD4 + 4 shows that T cell responses were successfully restored.
[0227] Example 7 - Immunogenicity evaluation of various adjuvanted recombinant protein HBc / HBs ratios the purpose The purpose of the study was to determine the HBc-induced CD4 T cell proliferation rate, as seen in Example 2 (HBsAg and HBcAg were mixed in a 1:1 ratio) 7 days after the third immunization. + The aim of the study was to confirm the negative interference of HBsAg on T cell responses. A further aim was to limit this interference and to inhibit at least the potent HBc-specific CD4 + To ensure a T cell response (while simultaneously generating robust HBc and HBs specific antibody responses), various ratios of HBs / HBc were evaluated.
[0228] research design Six to eight week old CB6F1 mice (30 mice per group) were cultured in 50 μl of AS01 B Or AS01 B-4 Mice were immunized intramuscularly (gastrocnemius) three times on days 0, 14 and 28 with various formulations (listed in Table 8) containing HBc and HBs antigens in the blood. CB6F1 mice were randomly assigned to one of the study groups. Evaluation of HBc and HBs specific T cell responses by intracellular cytokine staining (ICS) was performed using leukocytes collected 7 days after the second and third immunization from 6 pools of 5 mice / group. Serum was collected from individual mice 14 days after the second and third immunization and as a result of statistical sample size analysis, only serum from 20 randomized mice was tested for evaluation of HBc and HBs specific antibody total Ig responses.
[0229] [Table 8]
[0230] statistical analysis The non-inferiority of the HBc-HBs group compared with the corresponding HBc group was evaluated. + This non-inferiority is reached if the UL with 95% CI of the geometric mean ratio of T cell frequencies (%) is less than 2 7 days after Dose III. As this was an initial assessment and the criteria were not predefined, no adjustment for multiplicity was applied.
[0231] Two primary objectives were answered using an ANOVA (analysis of variance) model. The model included group (4–12) as a fixed effect, interactions, and a heteroscedastic model (identical variances between groups were not assumed) to determine the log10 CD4 + Frequencies were fitted. Using this model, geometric means (and their 95% CI) and geometric mean ratios and their 95% CI were estimated using inverse log10 transformation of the differences.
[0232] result Antigen-specific CD4+ T cell response All formulations showed potent anti-HBc and HBs specific CD4 antibodies after the second immunization. + Induced T cell responses (±1%). AS01 B-4 HBc-specific CD4 induced by a preparation containing equal amounts of HBc and HBs + The magnitude of the T cell response was B-4 There was a tendency for it to be lower when compared to the single group (Figure 23), but these differences were not statistically significant because the ratio was ±1.4 (p=0.143) (Figure 23). B-4 HBc-specific CD4 induced by a preparation containing equal amounts of HBc and HBs + The magnitude of the T cell response was B-4 When compared with the single group, it was statistically lower (GMR 0.391 and 95% CI [0.184-0.828]) (Figure 24). + The observation of interference of HBs on T cell responses was confirmed. When the antigens were formulated in a 4:1 ratio of HBc and HBs antigens, the interference was less pronounced. HBs-specific CD4 + No such negative effects were observed when looking at T cell responses (Figures 23 and 24).
[0233] By further increasing the HBc to HBs ratio, such HBc-specific CD4 + There was a trend towards a greater recovery of T cell responses (although not statistically significant) and the presence of total HBc-specific CD4 + The median T cell count was up to 1.7%.
[0234] HBs-specific CD8 + T cell responses were evaluated after the second and third immunizations (Figure 25). HBs-specific dose-ranging responses were observed after the second and third immunizations. After the third immunization, HBs-specific CD8 +T cell responses tended to be decreased when co-formulated with an equal amount of HBc antigen (GMR 0.66 and 95% CI [0.337 to 1.295]), but this ratio was not statistically significant (p=0.1717). + T cell responses were low to undetectable (less than 0.1%, data not shown).
[0235] Antigen-specific antibody response All formulations were AS01 after the second immunization. B-4 Co-formulation of HBs and HBc in a 1:1 ratio in the adjuvant system induced high and similar anti-HBc and HBs total Ig responses without the negative effects (Figure 26). Anti-HBc specific total Ig responses were boosted after the third immunization (Figure 27). AS01 B-4 When HBs and HBc were co-formulated in a 1:1 ratio in the adjuvant system, HBs interference was observed on the level of HBc-specific antibody response. The GMT ratio and 95% confidence interval were 1.88 [1.44; 2.44], with a p-value < 0.0001. Increasing the HBc to HBs ratio by 4 allowed recovery of the HBc humoral response, with a GMT ratio and 95% confidence interval of 1.37 [1.04; 1.80], with a p = 0.0262. As previously reported, HBc did not negatively affect the level of HBs-specific antibody response (Figures 26 and 27).
[0236] conclusion The results of these experiments demonstrated that the HBc-specific CD4 + It is shown that the negative interference of HBs on T cell and humoral responses was overcome for formulations with an HBc / HBs ratio of ≥ 4. As a result, a dose of 4 μg HBc and 1 μg HBs was selected for further preclinical experiments.
[0237] Sequence Listing SEQ ID NO: 1: Amino acid sequence of HBs JPEG2024161488000009.jpg24162
[0238] SEQ ID NO:2: Amino acid sequence of HBc truncation JPEG2024161488000010.jpg14162
[0239] SEQ ID NO: 3: Amino acid sequence of the spacer incorporating the 2A cleavage region of the foot-and-mouth disease virus JPEG2024161488000011.jpg658
[0240] SEQ ID NO: 4: Nucleotide sequence encoding a spacer incorporating the 2A cleavage region of the foot and mouth disease virus JPEG2024161488000012.jpg10162
[0241] SEQ ID NO: 5: Amino acid sequence of HBc-2A-HBs JPEG2024161488000013.jpg39158
[0242] SEQ ID NO: 6: Nucleotide sequence encoding HBc-2A-HBs JPEG2024161488000014.jpg54160JPEG2024161488000015.jpg71162
[0243] SEQ ID NO: 7: Amino acid sequence of hIi JPEG2024161488000016.jpg28161
[0244] SEQ ID NO: 8: Nucleotide sequence encoding hIi JPEG2024161488000017.jpg53162
[0245] SEQ ID NO: 9: Amino acid sequence of hIi-HBc-2A-HBs JPEG2024161488000018.jpg48164JPEG2024161488000019.jpg14163
[0246] SEQ ID NO: 10: Nucleotide sequence encoding hIi-HBc-2A-HBs JPEG2024161488000020.jpg185163
[0247] SEQ ID NO: 11: Amino acid sequence of HBc JPEG2024161488000021.jpg21162
[0248] SEQ ID NO: 12: Amino acid sequence of hIi alternative variant JPEG2024161488000022.jpg28161
[0249] SEQ ID NO: 13: Nucleotide sequence encoding hI alternative variant JPEG2024161488000023.jpg68162
[0250] SEQ ID NO: 14: Alternative nucleic acid sequence of hIi-HBc-2A-HBs JPEG2024161488000024.jpg111162JPEG2024161488000025.jpg71164
[0251] SEQ ID NO: 15: Alternative amino acid sequence of hIi-HBc-2A-HBs JPEG2024161488000026.jpg64163
[0252] References: JPEG2024161488000027.jpg233163JPEG2024161488000028.jpg234162JPEG2024161488000029.jpg230164JPEG2024161488000030.jpg164164
[0253] The present disclosure includes the following sequence information: SEQUENCE LISTING <110> GlaxoSmithKline Biologicals SA <120> HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS <130> PA24-466 <140> <141> 2018-12-14 <150> GB 1721068.3 <151> 2017-12-15 <160> 15 <170> PatentIn version 3.5 <210> 1 <211> 226 <212> PRT <213> Hepatitis B Virus <400> 1 Met Glu Asn Ile Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu Gln 1 5 10 15 Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu 20 25 30 Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro Val Cys 35 40 45 Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro Thr Ser 50 55 60 Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg Phe 65 70 75 80 Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu Val 85 90 95 Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile Pro Gly 100 105 110 Ser Thr Thr Thr Asn Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro Ala 115 120 125 Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr Asp 130 135 140 Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala Lys 145 150 155 160 Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu Leu 165 170 175 Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp Leu 180 185 190 Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser Ile 195 200 205 Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe Cys Leu Trp Val 210 215 220 Tyr Island 225 <210> 2 <211> 149 <212> PRT <213> Artificial <220> <223> Truncated HBC <400> 2 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Ile Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val 145 <210> 3 <211> 24 <212> PRT <213> Artificial <220> <223> spacer incorporating 2A <400> 3 Ala Pro Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly 1 5 10 15 Asp Val Glu Ser Asn Pro Gly Pro 20 <210> 4 <211> 72 <212> DNA <213> Artificial <220> <223> spacer incorporating 2A <400> 4 gcccctgtga agcagaccct gaacttcgac ctgctgaagc tggccggcga cgtggagagc 60 aatcccggcc ct 72 <210> 5 <211> 435 <212> PRT <213> Artificial <220> <223> HBc-2A-HBs <400> 5 Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Ile Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Asp Arg Gly Arg Ser Pro Arg Arg 145 150 155 160 Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg 165 170 175 Arg Ser Gln Ser Arg Glu Ser Gln Cys Ala Pro Val Lys Gln Thr Leu 180 185 190 Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly 195 200 205 Pro Met Glu Asn Ile Thr Ser Gly Phe Leu Gly Pro Leu Leu Val Leu 210 215 220 Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser 225 230 235 240 Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro Val 245 250 255 Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro Thr 260 265 270 Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg Arg 275 280 285 Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu Leu 290 295 300 Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile Pro 305 310 315 320 Gly Ser Thr Thr Thr Asn Thr Gly Pro Cys Lys Thr Cys Thr Thr Pro 325 330 335 Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro Thr 340 345 350 Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser Trp Ala Phe Ala 355 360 365 Lys Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser Leu 370 375 380 Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val Trp 385 390 395 400 Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr Ser 405 410 415 <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe Cys Leu Trp<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 420 425 430<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> Val Tyr Ile<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> 435<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <210> 6<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <211> 1305<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <212> DNA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <213> Artificial<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <220><h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <223> HBc-2A-HBs<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <400> 6<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> atggacatcg atcccctacaa ggaatttggc gccaccgtgg agctgctgag cttcctgccc 60<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> agcgacttct tccccagcgt gagggacctc ctggacaccg ccagcgccct gtacagggag 120<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> gccctggaat ctcccgagca ctgcagccca caccacaccg cactgaggca ggccatcctg 180<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> tgctggggag agctgatgac cctcgccacc tgggtgggca acaacctgga ggaccccgcc 240<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> agcagggacc tggtggtgaa ctacgtcaac accaacatgg gcctgaagat caggcagctg 300<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ctgtggttcc acatcagctg cctgaccttc ggcaggga ccgtgctgga gtacctggtg 360<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> agcttcggcg tgtggatcag gacacctccc gcctacagac cccccaacgc ccccatcctg 420 agcaccctgc ccgagaccac agtggtgagg ggggcaggtc acccaggagg 480 aggactccaa gccccaggag gaggagc cagagcccca ggagaggag gagccagagc 540 agggagagcc agtgcgcccc tgtgaagcag accctgaact tcgacctgct gaagctggcc ggcgacgtgg agagcaatcc cggccctatg agagcatca ccagcggctt cctgggcccc ctgctggtgc tgcaggcagg cttcttcctg ctgaccagga tcctgaccat cccccagagc 720 ctggacagct ggtggaccag cctgaacttc ctcggcggga gccccgtgtg cctgggccag 780 840. aacagccagt ctcccaccag caatcacagc cccaccagct gccccccaat ctgtcctggc taccggtgga tgtgcctgag gaggttcatc atcttcctgt tcatcctgct cctgtgcctg 900 atcttcctgc tggtgctgct ggactaccag ggaatgctgc cagtgtgtcc cctgatcccc 960 ggctcaacca ccactaacac cggcccctgc aaaacctgca ccacccccgc tcagggcaac 1020 agcatgttcc caagctgctg ctgcaccaag cccaccgacg gcaactgcac ctgcattccc 1080 atccccagca gctgggcctt cgccaagtat ctgtgggagt gggccagcgt gaggttcagc 1140 tggctcagcc tgctggtgcc cttcgtccag tggtttgtgg gcctgagccc caccgtgtgg 1200 ctgagcgcca tctggatgat gtggtactgg ggccccagcc tgtactccat cgtgagcccc 1260 ttcatcccccc tgctgcccat tttcttctgc ctgtgggtgt acatc 1305 <210> 7 <211> 229 <212> PRT <213> Artificial <220> <223> hIi <400> 7 With His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val 1 5 10 15 Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met 20 25 30 Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Lys Cys Ser Arg Gly Ala 35 40 45 Leu Tyr Thr Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala Gly Gln 50 55 60 Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg Leu Asp Lys 65 70 75 80 Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys 85 90 95 Leu Pro Lys Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro Leu 100 105 110 Leu Met Gln Ala Leu Pro Met Gly Ala Leu Pro Gln Gly Pro Met Gln 115 120 125 Asn Ala Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val Met His Leu 130 135 140 Leu Gln Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Ser Phe 145 150 155 160 Pro Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile Asp Trp 165 170 175 Lys Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu Met Ser 180 185 190 Arg His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys Glu Ser 195 200 205 Leu Glu Leu Glu Asp Pro Ser Ser Gly Gly Val Thr Lys Gln Asp Leu 210 215 220 Gly Pro Val Pro Met 225 <210> 8 <211> 696 <212> DNA <213> Artificial <220> <223> hIi <400> 8 atgcacagga ggaggagcag gagctgcagg gaggaccaga agcccgtgat ggacgaccag 60 cgcgacctga tcagcaacaa cgagcagctg ccaatgctgg gcaggaggcc cggagcaccc 120 gaagcaagt gcagcagggg cgccctgtac accggcttca gcatcctggt gaccctcctg 180 ctggccggcc aggcaccac cgcctatttc ctgtaccagc agcagggcag gctcgataag 240 ctgaccgtga cctcccagaa cctgcagctg gagaacctga ggatgaagct gcccaagccc 300 cccaagcccg tgagcaagat gaggatggcc acccccctgc tgatgcaggc tctgcccatg 360 ggggccctgc cccagggccc catgcagaac gccaccaaat acggcaacat gaccgaggac 420 cacgtgatgc acctgctgca gaacgccgat cctctgaagg tgtacccacc cctgaaaggc 480 agcttccccg agaacctcag gcacctgaag aacaccatgg agaccatcga ctggaaggtg 540 ttcgagagct ggatgcacca ctggctgctg ttcgagatga gccggcacag cctggagcag 600 aagcccaccg acgcccctcc caaggagagc ctcgagctcg aggacccaag cagcggcctg 660 ggcgtgacca agcaggacct gggccccgtg cccatg 696 <210> 9 <211> 628 <212> PRT <213> Artificial <220> <223> hIi-HBc-2A-HBs <400> 9 Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val 1 5 10 15 Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met 20 25 30 Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Lys Cys Ser Arg Gly Ala 35 40 45 Leu Tyr Thr Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala Gly Gln 50 55 60 Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg Leu Asp Lys 65 70 75 80 Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys 85 90 95 Leu Pro Lys Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro Leu 100 105 110 Leu Met Gln Ala Leu Pro Met Gly Ala Leu Pro Gln Gly Pro Met Gln 115 120 125 Asn Ala Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val Met His Leu 130 135 140 Leu Gln Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Ser Phe 145 150 155 160 Pro Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile Asp Trp 165 170 175 Lys Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu Met Ser 180 185 190 Arg His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys Glu Ser 195 200 205 Leu Glu Leu Glu Asp Pro Ser Ser Gly Gly Val Thr Lys Gln Asp Leu 210 215 220 Gly Pro Val Pro Met Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala 225 230 235 240 Thr Val Glu Leu Leu Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val 245 250 255 Arg Asp Leu Leu Asp Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu 260 265 270 Ser Pro Glu His Cys Ser Pro His His Thr Ala Leu Arg Gln Ala Ile 275 280 285 Leu Cys Trp Gly Glu Leu Met Thr Leu Ala Thr Trp Val Gly Asn Asn 290 295 300 Leu Glu Asp Pro Ala Ser Arg Asp Leu Val Val Asn Tyr Val Asn Thr 305 310 315 320 Asn Met Gly Leu Lys Ile Arg Gln Leu Leu Trp Phe His Ile Ser Cys 325 330 335 Leu Thr Phe Gly Arg Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly 340 345 350 Val Trp Ile Arg Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile 355 360 365 Leu Ser Thr Leu Pro Glu Thr Thr Val Val Ala Pro Val Lys Gln Thr 370 375 380 Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro 385 390 395 400 Gly Pro Met Glu Asn Ile Thr Ser Gly Phe Leu Gly Pro Leu Leu Val 405 410 415 Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln 420 425 430 Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn Phe Leu Gly Gly Ser Pro 435 440 445 Val Cys Leu Gly Gln Asn Ser Gln Ser Pro Thr Ser Asn His Ser Pro 450 455 460 Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr Arg Trp Met Cys Leu Arg 465 470 475 480 Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu Leu Cys Leu Ile Phe Leu 485 490 495 Leu Val Leu Leu Asp Tyr Gln Gly Met Leu Pro Val Cys Pro Leu Ile 500 505 510 Pro Gly Ser Thr Thr Thr Asn Thr Gly Pro Cys Lys Thr Cys Thr Thr 515 520 525 Pro Ala Gln Gly Asn Ser Met Phe Pro Ser Cys Cys Cys Thr Lys Pro 530 535 540 Thr Asp Gly Asn Cys Thr Cys Ile Pro Ile Pro Ser Ser Trp Ala Phe 545 550 555 560 Ala Lys Tyr Leu Trp Glu Trp Ala Ser Val Arg Phe Ser Trp Leu Ser 565 570 575 Leu Leu Val Pro Phe Val Gln Trp Phe Val Gly Leu Ser Pro Thr Val 580 585 590 Trp Leu Ser Ala Ile Trp Met Met Trp Tyr Trp Gly Pro Ser Leu Tyr 595 600 605 Ser Ile Val Ser Pro Phe Ile Pro Leu Leu Pro Ile Phe Phe Cys Leu 610 615 620 Trp Val Tyr Island 625 <210> 10 <211> 1998 <212> DNA <213> Artificial <220> <223> hIi-HBc-2A-HBs <400> 10 atgcacagga ggaggagcag gagctgcagg gaggaccaga agcccgtgat ggacgaccag 60 cgcgacctga tcagcaacaa cgagcagctg ccaatgctgg gcaggaggcc cggagcacccc 120 gaaagcaagt gcagcagggg cgccctgtac accggcttca gcatcctggt gaccctcctg 180 ctggccggcc agccaccac cgcctatttc ctgtaccagc agcaggcag gctcgataag 240 ctgaccgtga cctcccagaa cctgcagctg gagaacctga ggatgaagct gcccaagccc 300 cccaagcccg tgagcagat gaggatggcc acccccctgc tgatgcaggc tctcccatg 360 ggggccctgc cccaggggccc catgcagac gccaccaat accgaccacat catcacgac 420 cacgtgatgc acctgctgca gaacgccgat cctctgaagg tgtacccacc cctgaaaggc 480 agcttccccg agaacctcag gcacctgaag aacaccatgg agaccatcga ctggaaggtg 540 ttcgagagct ggatgcacca ctggctgctg ttcgagatga gccggcacag cctggagcag 600 aagcccaccg acgcccctcc caaggagagc ctcgagctcg aggacccaag cagcggcctg 660 ggcgtgacca agcaggacct gggccccgtg cccatggaca ttgaccccta caaggagttc 720 ggcgccaccg tcgaactgct gagcttctc cccagcgact tcttcccctc cgtgagggat 780 ctgctggaca cagctagcgc cctgtacagg gaggccctgg agagccccga gcactgcagc 840 ccccaccaca cagccctgag gcaggccatc ctctgttggg gcgagctgat gaccctggcc 900 acctgggtgg gcaataacct ggaggacccc gccagcaggg acctggtggt caactacgtg 960 aacaccaaca tgggcctgaa gatcaggcag ctgctgtggt tccacatcag ctgcctgacc 1020 tttggcaggg agaccgtcct ggagtacctg gtgagcttcg gcgtgtggat caggactccc 1080 ccagcctaca ggccccctaa cgcccccatc ctgtctaccc tgcccgagac caccgtggtg 1140 aggaggaggg acaggggcag aagccccagg agaaggaccc ctagccccag gaggagg 1200 agccagagcc ccaggaggag gaggagccag agccggggaga gccagtgcgc ccctgtgaag 1260. cagaccctga acttcgacct gctgaagctg gccggcgacg tggagagcaa tccccggccct atggaaaaca tcaccagcgg cttcctgggc cccctgctgg tgctgcaggc cggcttcttc ctgctgacca ggatcctgac cattccccag tcactggaca gctggtggac cagcctgac ttcctcggcg ggagccccgt gtgcctgggc cagaatagcc agagccccac cagcaaccac tctcccactt cctgcccccc tatctgcccc ggctacaggt ggatgtgcct gaggaggttc 1560 atcatcttcc tgttcatcct gctgctgtgc ctgatcttcc tgctggtgct gctggactac 1620 cagggaatgc tgcccgtgtg tcccctgatc cccggaagca ccaccaccaa caccggcccc 1680 tgcaagacct gcaccacccc cgcccagggc aactctatgt tccccagctg ctgctgcacc 1740 aagcccaccg acggcaactg cacttgcatt cccatcccca gcagctgggc cttcgccaaa 1800 tatctgtggg agtgggccag cgtgaggttt agctggctga gcctgctggt gcccttcgtg 1860 cagtggttg tgggcctgag ccccaccgtg tggctgagcg ccatctggat gatgtggtac 1920 tggggcccct ccctgtacag catcgtgagc cccttcatcc ccctcctgcc catctttctc 1980 tgcctgtggg tgtacatc 1998 <210> 11 <211> 185 <212> PRT <213> Hepatitis B Virus <400> 11 Put Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ala Thr Val Glu Leu Leu 1 5 10 15 Ser Phe Leu Pro Ser Asp Phe Phe Pro Ser Val Arg Asp Leu Leu Asp 20 25 30 Thr Ala Ser Ala Leu Tyr Arg Glu Ala Leu Glu Ser Pro Glu His Cys 35 40 45 Ser Pro His His Thr Ala Leu Arg Gln Ala Ile Leu Cys Trp Gly Glu 50 55 60 Leu Met Thr Leu Ala Thr Trp Val Gly Asn Asn Leu Glu Asp Pro Ala 65 70 75 80 Ser Arg Asp Leu Val Val Asn Tyr Val Asn Thr Asn Met Gly Leu Lys 85 90 95 Ile Arg Gln Leu Leu Trp Phe His Ile Ser Cys Leu Thr Phe Gly Arg 100 105 110 Glu Thr Val Leu Glu Tyr Leu Val Ser Phe Gly Val Trp Ile Arg Thr 115 120 125 Pro Pro Ala Tyr Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro 130 135 140 Glu Thr Thr Val Val Arg Arg Arg Asp Arg Gly Arg Ser Pro Arg Arg 145 150 155 160 Arg Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg 165 170 175 Arg Ser Gln Ser Arg Glu Ser Gln Cys 180 185 <210> 12 <211> 231 <212> PRT <213> Artificial <220> <223> hIi alternative variant <400> 12 Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val 1 5 10 15 Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met 20 25 30 Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Lys Cys Ser Arg Gly Ala 35 40 45 Leu Tyr Thr Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala Gly Gln 50 55 60 Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg Leu Asp Lys 65 70 75 80 Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys 85 90 95 Leu Pro Lys Pro Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro 100 105 110 Leu Leu Met Gln Ala Leu Pro Met Gly Ala Leu Pro Gln Gly Pro Met 115 120 125 Gln Asn Ala Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val Met His 130 135 140 Leu Leu Gln Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Gly 145 150 155 160 Ser Phe Pro Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile 165 170 175 Asp Trp Lys Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu 180 185 190 Met Ser Arg His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys 195 200 205 Glu Ser Leu Glu Leu Glu Asp Pro Ser Ser Gly Leu Gly Val Thr Lys 210 215 220 Gln Asp Leu Gly Pro Val Pro 225 230 <210> 13 <211> 693 <212> DNA <213> Artificial <220> <223> hIi alternative variant <400> 13 atgcacagga ggagaagcag gagctgtcgg gaagatcaga agccagtcat ggatgaccag 60 cgcgacctta tctccaacaa tgagcaactg cccatgctgg gccggcgccc tggggcccg 120 gagagcaagt gcagccgcgg agccctgtac acaggcttttt ccatcctggt gactctgctc 180 ctcgctggcc aggccaccac cgcctacttc ctgtaccagc agcagggccg gctggacaaa 240 ctgacagtca cctcccagaa cctgcagctg gagaacctgc gcatgaagct tcccaagcct 300 cccaagcctg tgagcaagat gcgcatggcc accccgctgc tgatgcaggc gctgcccatg 360 ggagccctgc cccaggggcc catgcagaat gccaccaagt atggcaacat gacagaggac 420 catgtgatgc acctgctcca gaatgctgac cccctgaagg tgtacccgcc actgaagggg 480 agcttcccgg agaacctgag acaccttaag aacaccatgg agaccataga ctggaaggtc 540 ttgagagct ggatgcacca ttggctcctg ttgaaatga gcaggcactc cttggagcaa 600 aagcccactg acgctccacc gaaagagtca ctggaactgg aggacccgtc ttctgggctg 660 ggtgtgacca agcaggatct gggcccagtc ccc 693 <210> 14 <211> 1998 <212> DNA <213> Artificial <220> <223> variant hIi-HBc-2A-HBs <400> 14 atgcacagga ggagaagcag gagctgtcgg gaagatcaga agccagtcat ggatgaccag 60 cgcgacctta tctccaacaa tgagcaactg cccatgctgg gccggcgccc tggggccccg 120 gagagcaagt gcagccgcgg agccctgtac acaggctttt ccatcctggt gactctgctc 180 ctcgctggcc aggccaccac cgcctacttc ctgtaccagc agcagggccg gctggacaaa 240 ctgacagtca cctcccagaa cctgcagctg gagaacctgc gcatgaagct tcccaagcct 300 cccaagcctg tgagcaagat gcgcatggcc accccgctgc tgatgcaggc gctgcccatg 360 ggagccctgc cccaggggcc catgcagaat gccaccaagt atggcaacat gacagaggac 420 catgtgatgc acctgctcca gaatgctgac cccctgaagg tgtacccgcc actgaagggg 480 agcttcccgg agaacctgag acaccttaag aacaccatgg agaccataga ctggaaggtc 540 tttgagagct ggatgcacca ttggctcctg tttgaaatga gcaggcactc cttggagcaa 600 aagcccactg acgctccacc gaaagagtca ctggaactgg aggacccgtc ttctgggctg 660 ggtgtgacca agcaggatct gggcccagtc cccatggaca ttgaccctta taaagaattt 720 ggagctactg tggagttact ctcgtttttg ccttctgact tctttccttc cgtcagagat 780 ctcctagaca ccgcctcagc tctgtatcga gaagccttag agtctcctga gcattgctca 840 cctcaccata ctgcactcag gcaagccatt ctctgctggg gggaattgat gactctagct 900 acctgggtgg gtaataattt ggaagatcca gcatccaggg atctagtagt caattatgtt 960 aatactaaca tgggtttaaa gatcaggcaa ctattgtggt ttcatatatc ttgccttact 1020 tttggaagag agactgtact tgaatatttg gtctctttcg gagtgtggat tcgcactcct 1080 ccagcctata gaccaccaaa tgcccctatc ttatcaacac ttccggaaac tactgttgtt 1140 agacgacggg accgaggcag gtcccctaga agaagaactc cctcgcctcg cagacgcaga 1200 tctcaatcgc cgcgtcgcag aagatctcaa tctcgggaat ctcaatgtgc ccctgtgaag 1260 cagaccctga acttcgacct gctgaagctg gccggcgacg tggagagcaa tcccggccct 1320 atggagaaca tcacatcagg attcctagga cccctgctcg tgttacaggc ggggtttttc 1380 ttgttgacaa gaatcctcac aataccgcag agtctagact cgtggtggac ttctctcaat 1440 tttctagggg gatcacccgt gtgtcttggc caaaattcgc agtccccaac ctccaatcac 1500 tcaccaacct cctgtcctcc aatttgtcct ggttatcgct ggatgtgtct gcggcgtttt 1560 atcatattcc tcttcatcct gctgctatgc ctcatcttct tattggttct tctggattat 1620 caaggtatgt tgcccgtttg tcctctaatt ccaggatcaa caacaaccaa tacgggacca 1680 tgcaaaacct gcacgactcc tgctcaaggc aactctatgt ttccctcatg ttgctgtaca 1740 aaacctacgg atggaaattg cacctgtatt cccatcccat cgtcctgggc tttcgcaaaa 1800 tacctatggg agtgggcctc agtccgtttc tcttggctca gtttactagt gccatttgtt 1860 cagtggttcg taggctttc ccccactgtt tggctttcag ctatatggat catgtggtat 1920 tgggggccaa gtctgtacag catcgtgagt ccctttatac cgctgttacc aattttctt 1980 tgtctctggg tatacatt 1998 <210> 15 <211> 666 <212> PRT <213> Artificial <220> <223> variant hIi-HBc-2A-HBs <400> 15 Met His Arg Arg Arg Ser Arg Ser Cys Arg Glu Asp Gln Lys Pro Val 1 5 10 15 Met Asp Asp Gln Arg Asp Leu Ile Ser Asn Asn Glu Gln Leu Pro Met 20 25 30 Leu Gly Arg Arg Pro Gly Ala Pro Glu Ser Lys Cys Ser Arg Gly Ala 35 40 45 Leu Tyr Thr Gly Phe Served With Leu Val Thr Leu Leu Leu Ala Gly Gln 50 55 60 Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg Leu Asp Lys 65 70 75 80 Leu Thr Val Thr Ser Gln Asn Leu Gln Leu Glu Asn Leu Arg Met Lys 85 90 95 Leu Pro Lys Pro Pro Lys Pro Val Ser Lys Met Arg Met Ala Thr Pro 100 105 110 Leu Leu Met Gln Ala Leu Pro Met Gly Ala Leu Pro Gln Gly Pro Met 115 120 125 Gln Asn Ala Thr Lys Tyr Gly Asn Met Thr Glu Asp His Val Met His 130 135 140 Leu Leu Gln Asn Ala Asp Pro Leu Lys Val Tyr Pro Pro Leu Lys Gly 145 150 155 160 Ser Phe Pro Glu Asn Leu Arg His Leu Lys Asn Thr Met Glu Thr Ile 165 170 175 Asp Trp Lys Val Phe Glu Ser Trp Met His His Trp Leu Leu Phe Glu 180 185 190 Met Ser Arg His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys 195 200 205 Glu Ser Leu Glu Leu Glu Asp Pro Ser Ser Gly Leu Gly Val Thr Lys 210 215 220 Gln Asp Leu Gly Pro Val Pro Met Asp Ile Asp Pro Tyr Lys Glu Phe 225 230 235 240 Gly Ala Thr Val Glu Leu Leu Ser Phe Leu Pro Ser Asp Phe Phe Pro 245 250 255 Ser Val Arg Asp Leu Leu Asp Thr Ala Ser Ala Leu Tyr Arg Glu Ala 260 265 270 Leu Glu Ser Pro Glu His Cys Ser Pro His His Thr Ala Leu Arg Gln 275 280 285 Ala Ile Leu Cys Trp Gly Glu Leu Met Thr Leu Ala Thr Trp Val Gly 290 295 300 Asn Asn Leu Glu Asp Pro Ala Ser Arg Asp Leu Val Val Asn Tyr Val 305 310 315 320 Asn Thr Asn Met Gly Leu Lys Ile Arg Gln Leu Leu Trp Phe His Ile 325 330 335 Ser Cys Leu Thr Phe Gly Arg Glu Thr Val Leu Glu Tyr Leu Val Ser 340 345 350 Phe Gly Val Trp Ile Arg Thr Pro Pro Ala Tyr Arg Pro Pro Asn Ala 355 360 365 Pro Ile Leu Ser Thr Leu Pro Glu Thr Thr Val Val Arg Arg Arg Asp 370 375 380 Arg Gly Arg Ser Pro Arg Arg Arg Thr Pro Ser Pro Arg Arg Arg Arg 385 390 395 400 Ser Gln Ser Pro Arg Arg Arg Arg Ser Gln Ser Arg Glu Ser Gln Cys 405 410 415 Ala Pro Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly 420 425 430 Asp Val Glu Ser Asn Pro Gly Pro Met Glu Asn Ile Thr Ser Gly Phe 435 440 445 Leu Gly Pro Leu Leu Val Leu Gln Ala Gly Phe Phe Leu Leu Thr Arg 450 455 460 Ile Leu Thr Ile Pro Gln Ser Leu Asp Ser Trp Trp Thr Ser Leu Asn 465 470 475 480 Phe Leu Gly Gly Ser Pro Val Cys Leu Gly Gln Asn Ser Gln Ser Pro 485 490 495 Thr Ser Asn His Ser Pro Thr Ser Cys Pro Pro Ile Cys Pro Gly Tyr 500 505 510 Arg Trp Met Cys Leu Arg Arg Phe Ile Ile Phe Leu Phe Ile Leu Leu 515 520 525 Leu Cys Leu Ile Phe Leu Leu Val Leu Leu Asp Tyr Gln Gly Met Leu 530 535 540 Pro Val Cys Pro Leu Ile Pro Gly Ser Thr Thr Thr Asn Thr Gly Pro 545 550 555 560 Cys Lys Thr Cys Thr Thr Pro Ala Gln Gly Asn Ser Met Phe Pro Ser 565 570 575 Cys Cys Cys Thr Lys Pro Thr Asp Gly Asn Cys Thr Cys Ile Pro Ile 580 585 590 Pro Ser Ser Trp Ala Phe Ala Lys Tyr Leu Trp Glu Trp Ala Ser Val 595 600 605 Arg Phe Ser Trp Leu Ser Leu Leu Val Pro Phe Val Gln Trp Phe Val 610 615 620 Gly Leu Ser Pro Thr Val Trp Leu Ser Ala Ile Trp Met Met Trp Tyr 625 630 635 640 Trp Gly Pro Ser Leu Tyr Ser Ile Val Ser Pro Phe Ile Pro Leu Leu 645 650 655 Pro Ile Phe Phe Cys Leu Trp Val Tyr Ile 660 665
Claims
1. 1. A method of treating chronic hepatitis B infection (CHB) in a human, comprising: a) administering to a human a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) administering to the human a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising recombinant Hepatitis B surface antigen (HBs), recombinant Hepatitis B core antigen (HBc) and an adjuvant. A method comprising:
2. 2. The method of claim 1, wherein the method steps are performed sequentially, with step a) preceding step b) and step b) preceding step c).
3. The method of claim 2 , wherein step c) of the method is repeated.
4. 4. The method of claim 1, wherein the period between each step is 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 12 weeks, 6 months, or 12 months, such as 4 weeks or 8 weeks.
5. The method of claim 1 , wherein step c) is carried out simultaneously with step a) and / or step b).
6. 1. A method of treating chronic hepatitis B infection (CHB) in a human, comprising: a) administering to a human i) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, concomitantly, ii) a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc), and an adjuvant; and b) administering to the human: i) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B core antigen (HBc), and, simultaneously, a composition comprising a recombinant hepatitis B surface antigen (HBs), a recombinant hepatitis B core antigen (HBc) and an adjuvant. A method comprising:
7. 1. An immunogenic combination for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic combination comprising: a) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) Compositions comprising recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B core antigen (HBc) and an adjuvant wherein the method comprises administering the compositions sequentially or simultaneously to a human.
8. An immunogenic composition for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs), a nucleic acid encoding hepatitis B core antigen (HBc), and a nucleic acid encoding human invariant chain (hIi) fused to HBc, the method comprising administering the composition in a prime-boost regimen with at least one other immunogenic composition.
9. The immunogenic composition for use according to claim 7, further comprising one or more recombinant HBV protein antigens.
10. An immunogenic composition for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc), the method comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition.
11. The immunogenic composition for use according to claim 9, further comprising one or more recombinant HBV protein antigens.
12. An immunogenic composition for use in a method of treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a recombinant hepatitis B surface antigen (HBs), a C-terminally truncated recombinant hepatitis B core antigen (HBc), and an adjuvant containing MPL and QS-21, the method comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition.
13. 13. The immunogenic composition for use according to claim 12, wherein the ratio of HBc to HBs in the composition is greater than 1.
14. 14. The immunogenic composition for use according to claim 13, wherein the ratio of HBc to HBs in the composition is 4:
1.
15. The immunogenic composition for use according to any one of claims 12 to 14, further comprising one or more vectors encoding one or more HBV antigens.
16. Use of an immunogenic composition in the manufacture of a medicament for treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding hepatitis B surface antigen (HBs), a nucleic acid encoding hepatitis B core antigen (HBc), and a nucleic acid encoding human invariant chain (hIi) fused to a nucleic acid encoding HBc, and a method of treating chronic hepatitis B infection comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition.
17. Use of an immunogenic composition in the manufacture of a medicament for treating chronic hepatitis B infection (CHB) in a human, the immunogenic composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding Hepatitis B surface antigen (HBs) and a nucleic acid encoding Hepatitis B core antigen (HBc), and a method of treating chronic hepatitis B infection comprising administration of the composition in a prime-boost regimen with at least one other immunogenic composition.
18. 1. Use of an immunogenic combination in the manufacture of a medicament for the treatment of chronic hepatitis B infection (CHB) in a human, the immunogenic combination comprising: a) a composition comprising a replication-deficient chimpanzee adenovirus (ChAd) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B core antigen (HBc); b) a composition comprising a modified vaccinia virus Ankara (MVA) vector comprising a polynucleotide encoding a Hepatitis B surface antigen (HBs) and a nucleic acid encoding a Hepatitis B virus core antigen (HBc); and c) Compositions comprising recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B core antigen (HBc) and an adjuvant wherein the method for treating chronic hepatitis B infection comprises administering the compositions sequentially or simultaneously to a human.
Citation Information
Cited By
Method for manufacturing semiconductor device and semiconductor manufacturing apparatus
CN121696792A
